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The principal objective of this study was to develop an alternative non-genetic rat model for 
type 2 diabetes (T2D). Six-week-old male Sprague-Dawley rats (190.56 ± 23.60g) were 
randomly divided into six groups namely: Normal Control (NC), Diabetic/Streptozotocin 
Control (STZ), Fructose-10 (FR10+STZ), Fructose-20 (FR20+STZ), Fructose-30 
(FR30+STZ) and Fructose-40 (FR40+STZ) and were fed a normal rat pellet diet ad libitum 
for 2 weeks. During this period, the two control groups received normal drinking water whilst 
the fructose groups received 10, 20, 30 and 40% fructose in drinking water ad libitum 
respectively. After two weeks of dietary manipulation, all groups except the NC group 
received a single injection (i.p.) of streptozotocin (STZ) (40mg/kg BW) dissolved in citrate 
buffer (pH 4.4). The NC group received only a vehicle buffer injection (i.p.). One week after 
the STZ injection, animals with non-fasting blood glucose >300 mg/dl were considered as 
diabetic. Three weeks after the STZ injection, the animals in FR20+STZ, FR30+STZ and 
FR40+STZ were eliminated from the study due to the severity of diabetes and the FR10+STZ 
group was selected for the remainder of the 11 weeks experimental period. The significantly 
(p < 0.05) higher fluid intake, blood glucose, serum lipids, liver glycogen, liver function 
enzymes and insulin resistance (HOMA-IR) and significantly (p < 0.05) lower body weight, 
oral glucose tolerance, number of pancreatic β-cells and pancreatic β-cell functions (HOMA-
beta) of FR10 group demonstrate that the 10% fructose-fed followed by 40 mg/kg of BW 
STZ injected rat can be an excellent alternative model for T2D. 
To validate this newly-developed model, an acute intervention trial study was conducted to 
investigate the anti-diabetic effects of L-Carnitine and white mulberry leaf tea extracts in the 
newly developed animal model of type 2 diabetes (T2D). Male Sprague-Dawley rats (mean 
BW 191.88g±16.40g) were randomly divided into 5 groups namely: Normal Control (NC), 
Diabetic/Streptozotocin control (FR10+STZ), Mulberry Tea Low (FR10+STZ+MTL, 
0.25%), Mulberry Tea High (FR10+STZ+MTH, 0.5%), and L-Carnitine 
(FR10+STZ+CARN). In first three weeks, T2D was induced in all other groups except NC 
group by using above-mentioned procedure. Mulberry tea was supplied ad libitum and L-
carnitine was administered to the FR10+STZ+CARN group at a concentration of 500mg/kg 
BW once daily during week 4-8 of the intervention trial. The FR10+STZ+CARN group had 
significantly (p < 0.05) lower total cholesterol, triglycerides, total proteins and fluid intake 
compared to the diabetic control (FR10+STZ). The NFBG non-significantly reduced in 
FR10+STZ+CARN group compared to the FR10+STZ group, whereas MT did not. 
FR10+STZ+MTL had significantly higher serum triglycerides level compared to the NC 
group, and significantly higher HDL-cholesterol and fluid intake compared to the FR10+STZ 
group. FR10+STZ+CARN and FR10+STZ+MT groups had significantly lower total proteins 
compared to NC and FR10+STZ groups, but significantly lower albumin compared to NC 
group only. The data of the this section of the study suggest that CARN may be effective in 
normalizing lipid profiles rather than blood glucose in diabetic rats which may aid in the 
reversal of insulin resistance. On the other hand, MT used in this study did not display any 
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CHAPTER 1 General Introduction and Literature Review 
1.1 Overview and global impact on diabetes 
Type 2 diabetes mellitus is one of the most complex diseases to define in the medical world. 
Diabetic patients are varied from non-obese subjects with mild glucose intolerance to obese 
patients with moderate symptoms that are either acutely or chronically expressed (Nattrass 
and Bailey, 1999). Diabetes is thus a complex, heterogeneous disorder, caused as a result of a 
plethora of both environmental and genetic factors (Cnop et al., 2005). Unlike Type 1 
diabetes (T1D), where T1D is denoted as diminished insulin production, Type 2 diabetes 
(T2D) is seen as an insidious condition (Liu et al., 2007). T2D is defined as impaired 
responses to insulin (insulin resistance) and progressive pancreatic β-cell dysfunction (Lin 
and Sun, 2010). Out of the total number of diabetic cases reported in Northern America, 
approximately 90-95% of them are Type 2 diabetics (Wing, 2008), with an estimated 20% of 
the population over the age of 65 suffering from T2D (Zimmet et al., 2001).  
Now-a-day diet and lifestyle choices tend toward high caloric intake and low physical 
activity, promoting the development of obesity. An increased risk of developing T2D has 
been linked to obesity through its association with diets of high caloric content (Marshall et 
al., 1994). Furthermore, it is estimated that 80% of Type 2 diabetics are associated with 
obesity (Lin and Sun, 2010). From 1935 to 1996, levels of T2D have risen an astounding 
765% (Basciano et al., 2005).  
High lipid levels in the blood stream seen in diabetics are also present in many obese 
individuals as fat secretes humoral factors including leptin, resistin and adiponectin that alter 
insulin sensitivity, leading to insulin resistance. This links obesity to a predisposition for the 
development of T2D (Trujillo and Scherer, 2006). This can be seen in the figures obtained 
from The International Obesity Task Force that estimated that there are approximately 300 
million individuals suffering from obesity (Reuter, 2007); 150 million of which are suffering 
from T2D (Srinivasan and Ramarao, 2007). In 2000, 171 million people were reported to 
have T2D, (over 800 000 in South Africa), and this figure is predicted to rise to over 360 
million by 2030 (with 1.2 million in South Africa) (WHO, 2010). This figure is alarming as 
T2D is the fourth major cause of death in South Africa (Joubert et al., 2007) after HIV/AIDS, 
heart disease and respiratory infections. The socio-economic consequences of this disease are 
significant, as it is estimated that in 9 years (2006-2015), major world powers such as China 
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will lose over $558 billion from national income, due to diabetes and its complications 
(WHO, 2010).  
Table 1: Projection of type 2 diabetic patients according to the World Health 
Organization (2010) 
   2000  2030  
World  171,000,000  366,000,000 
South Africa  814,000  1,286,000  
As mentioned above, T2D is classified according to two major pathogeneses presented as 
insulin resistance i.e. insulin insensitivity and impaired pancreatic β-cell function (DeFronzo, 
1992). Insulin resistance is defined as an increase in insulin secretion in order to allow for a 
normal biological response from defective target tissues (Kural et al., 2007). Insulin 
resistance is an early feature of T2D largely linked to abdominal obesity, high intake of 
dietary carbohydrate with minimal physical activity, aging and several genetic factors 
(Stumvoll et al., 2005; Kural et al., 2007). Insulin insensitivity arises primarily from glucose 
storage target tissues such as skeletal muscle and the liver (Caro, 1990). Due to insulin 
resistance, pancreatic β-cells secrete abnormally high levels of insulin in order to control 
blood glucose levels, however overtime; hyperglycemia, hyperinsulinemia, pancreatic β-cell 
dysfunction and subsequent progressive pancreatic β-cell destruction occur (Stumvoll et al., 
2005; Liu et al., 2007; Srinivasan et al., 2005).  
Insulin secretions occur in a biphasic fashion. First phase insulin secretions become impaired 
in type 2 diabetic patients, leading to a hyperglycaemic state. To compensate for 
hyperglycemia, a second, more pronounced insulin response occurs, which leads to 
hyperinsulinemia. As the disease progresses, even the second-phase insulin secretion 
response becomes impaired (Nattrass and Bailey, 1999). T2D is therefore noted as raised 
fasting blood glucose levels above that deemed to be normal as well as abnormally high 
postprandial blood glucose levels (Islam, 2011; Rees and Alcolado, 2005). Normal fasting 
blood glucose levels are below 100 mg/dl or less than 5.5 mmol/L, whilst impaired glucose 
tolerance is defined as mild hyperglycemia in the fasted state with blood glucose levels 
ranging between 120-140 mg/dl or 6.7-7.8 mmol/L. A full blown T2D state is defined as 
overt fasting hyperglycemia with blood glucose levels exceeding 140 mg/dl or greater than 
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7.8 mmol/L (De Fronzo, 1992). Whilst diagnostic characteristics defining T2D are well 
established, the mechanisms behind the onset of T2D remain largely obscure, although 
several mechanisms of action have already been reported. Many of these reported involve 
increased levels of non-esterified fatty acids, inflammatory cytokines, adipokines, 
glucotoxicity, lipotoxicity, mitochondrial dysfunction as well as amyloid formation resulting 
in pancreatic β-cell dysfunction (Stumvoll et al., 2005). The heterogeneity of this disease 
does not only stem from environmental factors, as there is a significant genetic component 
that influences the progression of this disease. Research in this area is limited, as only a few 
genes have been identified which play a role in the development of T2D. It is known that 
amongst identical twins there is a 90% concordance for the development of T2D (Marshall 
and Bangert, 2008). Abnormalities in genes such as glucokinase, calpain 10, potassium 
inward-rectifier 6.2, peroxisome proliferator-activated receptor γ (PPAR-γ) and insulin 
receptor substrate-1 (IRS-1) have been linked to the progression of T2D (Stumvoll et al., 
2005). 
1.2 Carbohydrate metabolism and biochemistry of insulin 
Under normal carbohydrate metabolic conditions, pancreatic β-cells constantly produce 
insulin at a basal concentration irrespective of the blood glucose level. Following 
consumption of a carbohydrate-rich meal, complex carbohydrates are primarily metabolized 
by the salivary amylase in the mouth and broken down into disaccharide units. These are then 
hydrolytically split into monosaccharide units, largely comprising of glucose, fructose and 
galactose. These monosaccharides are then absorbed by the small intestinal mucosal cells and 
enter into the blood stream. Glucose is transported predominantly to the liver, where 
glucokinase, a rate-limiting enzyme of glycolysis responsible for glucose phosphorylation to 
glucose-6-phosphate, promotes glucose utilization (Figure 1). 
Figure 1: Overview of the cellular metabolism of carbohydrates (Copied without 
permission from Ramakrishnan et al., 2001). 
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Glucose enters pancreatic β-cells via a GLUT-2 receptor and is metabolized by the rate-
limiting enzyme, glucokinase, to glucose-6-phosphate. This then follows through the 
glycolytic pathway to form pyruvate, which enters into the mitochondria to generate energy 
in the form of ATP. This establishes an ATP/ADP ratio, which stimulates the opening of the 
ATP-sensitive potassium (K+) channel. There is an efflux of potassium ions, resulting in the 
depolarisation of the cell. This allows for calcium ions (Ca2+) to enter into the cell such that it 
is repolarised. Calcium ions exert an effect on proinsulin granules by modifying over 90% to 
the active form of insulin, that is then translocated to the plasma membrane of the pancreatic 
cells (Marshall and Bangert, 2008) (Figure 2). 
 
Figure 2: Mechanism of insulin secretion (Copied without permission from Wing, 2008) 
where GTR-2 = GLUT-receptor-2. 
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Upon elevation of the blood glucose levels, insulin stored in vacuoles is released into the 
blood stream, thereby regulating glucose uptake from the blood into skeletal muscle and 
adipose tissue (Figure 2) (Lin and Sun, 2010). For normal insulin function, it must bind 
correctly to its specific receptor, which allows for amplification of its signal via secondary-
messenger pathways. These then allow for regulation and control of both cytoplasmic and 
genomic functions of insulin. Insulin signaling and transmission occurs through 
autophosphorylation of tyrosine residues within the receptor by the activation of insulin 
receptor tyrosine kinase activity. Several intracellular proteins are involved in this process 
and are known as insulin-receptor substrates (IRS). Dependent on the phosphorylation of 
these, the insulin signal is directed toward different metabolic pathways (Nattrass and Bailey, 
1999). Insulin resistance is thus a primary hallmark feature of T2D, associated with a 
malfunction in the cells that respond to insulin (i.e. post-receptor) (Lin and Sun, 2010).  
Insulin serves to function as an antihyperglycaemic agent by several means including: 
reducing the production of gluconeogenic precursors such as lactate, alanine and glycerol, 
reducing hepatic gluconeogenic enzyme activity, reducing hepatic breakdown of glycogen 
(glycogenolysis) to glucose, which result in a lower hepatic glucose output and instead, a 
promotion of glucose storage in muscles as glycogen (Marshall and Bangert, 2008).  
With lower blood glucose levels, the demand for insulin decreases and conversely stimulates 
the release of glucagon from the pancreatic α-cells, stimulating glycogen conversion back to 







Figure 3: Roles of insulin and glucagon on carbohydrate metabolism and blood glucose 




1.3 Biochemical features of T2D 
T2D leads to excessive urine production (polyuria), increased thirst (polydipsia), increased 
hunger (polyphagia), altered or affected vision (retinopathy), and major changes in energy 
metabolism such as hyperglycemia, hyperlipidemia and hyperinsulinemia (Lin and Sun, 
2010). Fasting hyperinsulinemia, another early stage hallmark feature of T2D, results from a 
number of mechanisms including elevated levels of free fatty acids (FFAs) in circulation, 
which increase insulin secretion (Zhou et al., 1999). Altered fatty acid metabolism has long 
been linked to insulin resistance (Shulman, 2000). The mechanism proposed for this (Figure 
4) is known as the Randle cycle, which proposes that increases in fatty acids raise both 
intramitochondrial acetyl CoA/CoA and NADH/NAD+ ratios. This leads to an inactivation of 
the enzyme pyruvate dehydrogenase, which increases intracellular concentrations of citrate. 
Citrate is a key-regulator of the glycolytic enzyme phosphofructokinase. Increases in citrate 
lead to a negative-feedback loop such that phosphofructokinase activity is inhibited. As 
phosphofructokinase is responsible for the conversion of glucose-6-phosphate to glucose-1,6-
bisphosphate, its inhibition thus leads to an accumulation of glucose-6-phosphate. This in 
turn leads to an inhibition of hexokinase/glucokinase, responsible for the formation of 
glucose-6-phosphate from hexose sugars and glucose respectively. This means no 
phosphorylation of glucose occurs, resulting in accumulation of intracellular glucose by 
means of decrease glucose uptake by cells causing high blood sugar levels or hyperglycemia 
(Shulman, 2000). This sustained hyperglycemia results in increased insulin secretion in an 





Figure 4: Mechanism of fatty acid induced insulin resistance (Copied without 
permission from Shulman, 2000, where HK = hexokinase, PFK = phosphofructokinase, 
PDH = pyruvate dehydrogenase, G-6-P = glucose-6-phosphate). 
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An alternative mechanism has also been proposed for fatty-acid induced insulin resistance in 
skeletal muscle (Figure 5). Alterations in fatty acid metabolism caused through a decrease in 
fatty acid metabolism result in increased intracellular concentrations of fatty acids and their 
metabolites such as fatty acyl CoA, diacylglycerol and ceramides. These metabolites are 
responsible for the activation of the serine/threonine kinase cascade, whereby serine or 
threonine residues become phosphorylated. When this occurs on the insulin receptor 
substrates 1 and 2 (IRS-1 and IRS-2) sites, the ability of IRS-1/IRS-2 to further activate PI 3-
kinase becomes diminished. This plays an important role in insulin signaling pathways and as 
a consequence leads to reduced glucose transport by GLUT-4 receptors. Non-entry of glucose 
into skeletal muscle results in increases in blood glucose levels causing hyperglycemia and 
insulin resistance as a result of diminished insulin signaling (Shulman, 2000). 
 
Figure 5: Alternative mechanism of fatty acid-induced insulin resistance (Copied 
without permission from Shulman, 2000) 
Another characteristic feature of T2D, hyperglycemia, results from 3 main effects namely 
increased hepatic glucose production, lowered insulin secretion and finally an impairment in 
insulin action (insulin resistance) (Stumvoll et al., 2005). As insulin resistance arises from 
impairment in insulin functioning in the liver, liver-related biochemical pathways including 
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gluconeogenesis, glycogenolysis, glycogen synthesis and glycolysis become defective. 
Insulin resistance in the liver thus leads to an inability to suppress the hepatic production of 
glucose. Fasting hyperglycemia (described earlier as blood glucose levels exceeding 140 
mg/dl) in T2D patients has been attributed mainly due to increased hepatic glucose 
production (Caro, 1990). Hepatic glucose production in T2D is caused primarily as a result of 
increased gluconeogenesis, which most likely occurs due to a variety of mechanisms 
including those discussed above including chronically elevated levels of FFAs that activate 
gluconeogenic enzymes and elevated circulating levels of lactate, glycerol and alanine which 
are all important precursors for gluconeogenesis (Caro, 1990). 
1.4 Current diabetes research 
The World Health Organisation predicts that over 330 million people worldwide will have 
diabetes by 2030, and the percentages of national health care budgets to diabetes alone, are 
estimated at 5-10% (WHO, 2010). Of the diabetic cases, 90-95% of them suffer from Type 2 
diabetes (T2D) (Chen and Wang, 2005). Due to its heterogeneous nature characterized by 
insulin resistance and pancreatic ß-cell dysfunction, it is essential to have appropriate means 
to study the molecular basis of the disease as well as advancing the knowledge on its 
pathogenesis including the environmental and genetic factors that contribute to the 
development of the disease. Furthermore, with the prevalence of T2D on the rise, drug 
development research and intensive studies into drug mechanistics have sharply increased; 
with the majority of this work being performed on animal models (Islam and Loots, 2009). 
Wall and Shani (2008) describe an animal model as “a living organism in which the 
phenomenon of interest can be studied and in which the phenomenon resembles that in the 
target animal in some respect.” This allows one to study the biochemical mechanistics in an 
animal model and predict the outcome in another e.g. study a human disease state in an 
animal. Animal models are largely valuable to medicinal studies as biochemical pathways 
between mammals are largely conserved (Wall and Shani, 2008).  
1.5 Materials used to induce diabetes for model development 
1.5.1 Streptozotocin 
Streptozotocin (STZ) is a natural antibiotic produced from the bacterial species Streptomyces 
achromogenes (Rees and Alcolado, 2005). It is a nitrosurea derivative and structural analogue 
of N-acetylglucosamine (GlcNAc) (Konrad et al., 2001) that acts as a potent alkylating agent 
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that results in disrupted glucose transport, glucokinase activity as well as induction of 
multiple DNA strand breaks (Figure 6) (Bolzan and Bianchi., 2002).   
 
Figure 6: Structures of N-acetylglucosamine and STZ (Copied without permission from 
Konrad et al., 2001). 
Streptozotocin (STZ) is able to enter pancreatic β-cells through GLUT-2 receptors resulting 
in DNA damage through alkylation as well as cause the generation of toxic superoxide and 
hydroxyl radicals. These radicals result in the destruction of the pancreatic β-cells by necrotic 
mechanisms (Szkudelski, 2001). For this reason the use of STZ in diabetic research is 
commonly employed as it serves as a non-surgical method for the induction of hyperglycemia 
and progressive pancreatic β-cell destruction (Rees and Alcolado, 2005). Its use in induction 
of diabetes has been critical as it selectively targets pancreatic β-cells through the alkylation 
of their DNA, therefore being of major use in both T1D and T2D research (Zhang et al., 
2008). Streptozotocin (STZ) has also been found to be selective for the destruction of 
pancreatic β-cells as it inhibits the enzyme O-GlcNAc-selective-N-acetyl-β-D-
glucosaminidase, which is responsible for the removal of O-GlcNAc from proteins. Protein 
glycosylation occurs when glucose is phosphorylated to glucose-6-phosphate and then 
transformed to fructose-6-phosphate under typical glycolytic processes. This is then 
converted to glucosamine-6-phosphate by glutamine:fructose-6-phosphate amidotransferase 
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(GFAT). This conversion provides precursors to UDP-GlcNAc, which is the necessary 
component in protein glycosylation. O-glycosylation in pancreatic β-cells takes place due to 
the enzyme O-GlcNAc transferase (OGT). This enzyme is expressed in substantially higher 
levels in the pancreatic β-cells than any other cell type in the body. STZ, thus, has been 
proposed to be selectively toxic to the pancreatic β-cells, leading to diabetic states (Konrad et 
al., 2001). 
The residual pancreatic β-cell mass that remains after STZ administration is estimated at 
20%, however progressively increases to 50% due to pancreatic β-cell regenerative 
mechanisms (Masiello, 2006). Single high dose STZ injections result in massive pancreatic 
β-cell destruction, more characteristic of T1D, whereas low dose STZ injections cause only 
partial impairment to insulin secretory mechanisms seen in T2D (Srinivasan et al., 2005).  
1.5.2 Fructose 
Fructose consumption in the modern world has vastly increased – not only from traditional 
intake of fruit, but largely as a result of being a constituent of many soda drinks and artificial 
sweeteners such as high fructose corn syrup (HFCS) (Benado et al., 2004) (containing 
between 55-90% fructose) (Bray et al., 2004) as well as from a high intake of sucrose 
(Basciano et al., 2005). In 1970, it was estimated that the average individual consumption of 
fructose per annum was 0.5lb, which sharply rose to 62.4 lbs per annum in 1997 (Basciano et 
al., 2005). Research indicates that the dietary intake of fructose in the United States of 
America today stands at approximately 10% of the total energy consumption, bearing in mind 
that only one third of the American population is deemed as “normal weight” (Kahn et al., 
2006). There is a great need for concern with regards to high-fructose intake and 
development of T2D. This is because studies done by Gross et al. (2004) revealed that 
nutrient consumption in the USA between 1909 and 1997 showed a significant correlation in 
the occurrence of T2D with carbohydrates, lipids, high-fructose corn syrups and calorie 
intake. However, taking into account the total calorie intake, protein and fat intake, only 
HFCS was associated with T2D.  
Fructose has been labeled responsible largely for dietary-induced metabolic disturbances. 
Diets high in fructose cause weight gain, hyperlipidemia and hypertension in various animal 
models (Hwang et al., 1987). Fructose has been shown to be more hyperlipidemic than both 
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glucose and starch through the causation of a dramatic increase in VLDL and LDL 
contributing to the increase in total cholesterol levels (Benado et al., 2004). 
Studies have shown that rodents fed dietary fructose at levels of 20% and greater were 
hyperlipidemic, with both serum total cholesterol and non-HDL cholesterol being 
significantly elevated (p < 0.05) (Benado et al., 2004). This is of importance as diets 
containing 20% of the energy intake as fructose is approximately equal to the 90th percentile 
of fructose consumption in the American population.  
Fructose is widely known for its potential to exacerbate hyperlipidemia. It has been suggested 
that because fructose enters the liver unrestrictedly without the need for a GLUT receptor, 
fructose metabolism is unique in that it can bypass several critical steps of the glycolytic 
pathway. This includes the need for insulin to activate glucokinase as well as the action of 
phosphofructokinase that, in the case of glucose, catalyses the conversion of glucose-6-
phosphate to fructose-1,6-bisphosphate. Instead, fructose enters glycolysis or 
gluconeogenesis at the triosephosphate level in the liver (Benado et al., 2004). This provides 
an important difference between glucose and fructose metabolism and their implications in 
diabetes. Glucose, as opposed to fructose, is therefore negatively regulated by 
phosphofructokinase, whereas fructose can unrestrictedly enter into the glycolytic pathway. 
This leads to the uncontrollable production of glucose by gluconeogenesis, as well as 
production of glycogen, pyruvate and lactate in glycolysis, leading to lactic acid formation 
involved in metabolic acidosis seen in diabetics. 
Fructose is phosphorylated by fructokinase to yield fructose-1-phosphate, which is then split 
into two 3-carbon compounds namely glyceraldehyde and dihydroxyacetone phosphate. High 
concentrations of these provide excess acyl through the activation of pyruvate dehydrogenase 
and also glycerol molecules for triglyceride formation. This leads to esterification of fatty 
acids and their subsequent secretion as VLDL particles (Basciano et al., 2005) and ultimately 
enhanced hepatic lipogenesis (See Figure 7). Furthermore, fructose does not appear to 
stimulate lipoprotein lipase (Kohen-Avramoglu et al., 2003), which may result in reduced 
clearance of triglycerides from the plasma (Benado et al., 2004). This has been a major 
contributing factor to the dyslipidemia noted in diabetic patients (Basciano et al., 2005). In 
addition, studies have shown that fructose plays a key role in lipid synthesis as mice that 
followed a 7 day diet consisting of 60% fructose expressed an isoform of hepatic sterol 
regulatory element binding protein (SREBP) – a crucial transcription factor that regulates 
12 
 
both cholesterol and fatty acid synthesis. Fructose, unlike glucose, does not stimulate insulin 
nor does it stimulate leptin, which are both important for fat deposition in the body as well as 
energy intake regulation (Basciano et al., 2005).  
Figure 7: Diagrammatic representation of fructose metabolism (Copied without 
permission from Basciano et al., 2005) ApoB = Apolipoprotein B, MTP = Microsomal 
triglyceride transfer protein, P = phosphate, VLDL= Very low density lipoprotein 
A novel hypothesis proposes that fructose is capable of increasing levels of uric acid, which 
in turn, limit the availability of nitric oxide. Nitric oxide is required by insulin to stimulate the 
uptake of glucose from the blood stream, hence it is postulated that fructose is indirectly 
involved in promoting insulin resistance (Reuter, 2007). Studies in Australia at the Human 
Nutrition Research Center showed that fructose is also problematic as it is responsible for the 
depletion of chromium stores within the body. Chromium is important for diabetic patients as 
it is an essential mineral that aids the body in lowering blood glucose levels by acting in 
concert with GLUT receptors to facilitate entry of glucose into liver cells for further 
metabolism (Tondo, 2005). Furthermore, excessive fructose intake has been reported to alter 
protein oxidation biomarkers in the blood and enhance oxidative stress responses in vivo 
(Basciano et al., 2005). 
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Whilst fructose is known to cause in insulin resistance, it is also indirectly linked to 
progressive pancreatic β-cell destruction. This is because insulin resistance, chronic 
hyperglycemia and hyperlipidemia as well as oxidative stress lead to activation of 
proinflammatory cytokines all induced by chronic fructose intake and subsequently trigger 
apoptotic mechanisms in pancreatic β-cells (Lin and Sun, 2010). Fructose has also been 
found to affect insulin sensitivity through its ability to reduce adiponectin responses; an 
adipocyte hormone that plays a vital role in insulin action and lipid homeostasis (Basciano et 
al., 2005). Furthermore T2D has been linked to cardiovascular disease and elevated 
homocysteine levels are an important marker for cardiovascular disease. Interestingly, a study 
revealed that rats fed a fructose-rich diet had a 72% higher homocysteine level as opposed to 
the control, fed on regular chow (Basciano et al., 2005), implying that fructose plays a role in 
the development of cardiovascular disease, a downstream complication of T2D. 
1.5.3 Anti-diabetic drugs for model validation 
1.5.3.1 Metformin 
There are 7 major types of medication used in the treatment of diabetes namely insulin, 
sulfonylureas such as glibenclamide (commonly known as glyburide), biguanides such as 
metformin (commonly known as glucophage), alpha glucosidase inhibitors such as acarbose, 
thiazolidinediones such as pioglitazone and less commonly phenylalanine derivatives and 
meglitinides (Setter et al., 2003). Metformin, a biguanide, is derived from its parent 
compound, guanidine, originally found in the plant Galega officinalis (Goat’s rue or French 






Figure 8: Chemical structure of metformin (Copied without permission from Setter et 
al., 2003). 
Today, metformin is the most widely used anti-diabetic drug in the world (Grisouard et al., 
2010) and  has been a well-known drug for over half a century for the treatment of T2D 
(Howlett and Bailey, 1999). Metformin can be used in monotherapy or in conjunction with 
other treatments such as combinations with insulin or sulfonylureas (Campbell et al., 1996). 
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Unlike sulfonylureas (e.g. glibenclamide), metformin does not increase insulin secretion 
(Howlett and Bailey, 1999), but rather improves hepatic sensitivity to insulin thereby aiding 
in the reduction of both fasting and postprandial blood glucose (Dunn and Peters, 1995). 
Metformin therefore does not result in hypoglycemia, nor does it cause weight gain, due to 
the fact that it does not increase insulin secretion as is the case with insulin and sulfonylureas 
(Campbell et al., 1996). Furthermore, the two other major functions of metformin are that it 
reduces hepatic glucose production whilst also improving peripheral glucose uptake (Leverve 
et al., 2003).  
Figure 9: Mechanism of action of metfomin (Copied without permission from Defronzo 
et al., 1991). 
The precise cellular mechanisms by which metformin acts are still poorly understood 
(Leverve et al., 2003). One mechanism involves the ability of metformin to activate AMP-
activated protein kinase (AMPK), which is a key regulatory enzyme in energy homeostasis 
within the body (Zhou et al., 2001). Literature indicates that metformin diminishes both 
cellular respiratory functions and mitochondrial function through the inhibition of the 
enzymatic activity of complex I in the respiratory chain both in skeletal muscle and 
hepatocytes (Detaille et al., 2002). Grisouard et al. (2010) suggest that AMPK might also be 
activated in response to the inhibition of complex I. Metformin can thus serve to enhance 
glucose transport and glycolysis, as inhibition of the respiratory chain can be associated with 
an increase in the expression of glucose transporters and glycolytic enzymes. This serves to 
dramatically increase glucose utilization, thus lowering blood glucose levels (Grisouard et al., 
2010). In animal studies, metformin increases tyrosine kinase activity, which is involved in 
insulin signaling (Del Prato et al., 1995). Enhancement of tyrosine kinase improves both 
skeletal glucose utilization and glycogen synthesis, further reducing blood glucose levels. 
Metformin has also been found to produce some beneficial results for lipid profiles. It has 
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been shown to successfully reduce total cholesterol, triglycerides and LDL cholesterol. It has 
however, shown no significant increases to high density lipoprotein (HDL) cholesterol levels 
(Trischetta et al., 1992).  
1.5.3.2 Glibenclamide 
Glibenclamide (Figure 10) also known as glyburide (Langer et al., 2000) is a second-
generation sulphonylurea antidiabetic drug used in the treatment regiments of Type 2 
diabetics (Caro, 1990). This drug is used to increase plasma concentrations of insulin, whilst 
decreasing plasma concentrations of both glucose and non-esterified fatty acids. It achieves 
the increase in insulin secretion by stimulating insulin release from the pancreatic β-cells. It 
is, however, universally accepted that glibenclamide is not effective if pancreatic β-cells are 
non-functional or damaged to a large degree, as research has shown in both animal models 
and human clinical trials (Musbah and Furman, 1980; Stocks et al., 1988). Glibenclamide 
also produces extrapancreatic effects by improving the effect of insulin on target tissues such 
as the liver (Caro, 1990, Tanira and Furman, 1999). It has been shown to enhance the action 
of insulin (increase insulin sensitivity) in the liver and concurrently decreases gluconeogenic 
activity. It achieves its hypoglycaemic effects by several mechanisms: increasing glycogen 
synthesis by stimulating glycogen synthase, inhibiting glycogen catabolism (glycogenolysis) 
by reducing phosphorylase α activity and finally suppressing gluconeogenesis, increasing 
metabolic pathway flux to glycolysis by decreasing A-kinase activity resulting in increased 
fructose 2,6-bisphosphate – a key regulator in carbohydrate metabolism (Caro, 1990). 
 
Figure 10: Structure of Glibenclamide (Copied without permission from Nattrass and 
Bailey, 1999) 
In vivo studies by McGuinness and Cherrington (1990) determined the ability of 
glibenclamide to enhance insulin’s opposing effect on the gluconeogenic hormone, glucagon. 
They found that in the absence of insulin (as seen in T1D patients), glibenclamide could not 
diminish the action of glucagon. In the presence of sufficient insulin, however, glibenclamide 
decreased both hepatic glucose production and phosphorylase α (a key enzyme involved in 
the breakdown of glycogen into individual glucose units) by 40% and 50% respectively 
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(McGuinness and Cherrington, 1990). This is important to note as it shows that 
glibenclamide is not a direct inhibitor of glucagon, but rather improves the action of insulin.  
In vitro studies performed by Davidson and Sladen (1987) measured the catabolism of 
prelabeled glycogen and anabolism of glycogen through the incorporation of [14C] glucose. 
Glibenclamide significantly reduced glycogen breakdown and instead, favoured its synthesis 
by stimulation of glycogen synthase. Glibenclamide also activates other major biochemical 
pathways such as the glycolytic pathway by enhancing the action of a major rate-limiting 
enzyme of this pathway, glucokinase, which phosphorylates glucose to glucose-6-phosphate. 
This thereby commits glucose to be metabolized by the liver to either generate energy or in 
excess amounts, be stored as glycogen in muscle or fat in adipose tissue. Further evidence of 
glibenclamide action comes from the compound fructose-2,6-bisphosphate (F-2,6-P2), which 
can alter major rate-limiting enzymes of glycolysis and gluconeogenesis i.e. 
phosphofructokinase and fructose 1,6-bisphosphatase respectively as seen below (Caro, 
1990). 
 
Figure 11: Biochemical reaction and enzymes in fructose derivative reactions (image 
self drawn) 
This compound in higher concentrations activates phosphofructokinase and hence glycolysis. 
Interestingly, diabetic animals possess lower concentrations of F-2,6-P2 in the liver, which 
may provide an important reason for increased gluconeogenesis and decreased glycolysis 
seen in T2D. Glibenclamide has been found to enhance F-2,6-P2 formation in a dose-
dependent manner. Deeper insight reveals that biochemically, formation of F-2,6-P2 is 
controlled by a bifunctional enzyme (Fructose-6-phosphate-2-kinase-fructose-2,6-
bisphosphatase) (Caro, 1990).  
1.6 Overview of current animal models of T2D 
1.6.1 Genetic models of T2D 
Genetic models for T2D research have widely been employed over the last few decades. 
Some of the available models include the Zucker diabetic fatty (ZDF) rat, Goto Kakizaki 
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(GK) rats, Otsuka Long Evans Tokushima Fatty (OLETF) rats, spontaneously diabetic Tori 
(SDT) rats as well as genetically developed db/db+/+ (Islam and Loots, 2009). Several knock-
out models in mice have been developed and present with molecular pathologies of the 
disease yet often fail to exhibit exact symptoms of T2D (Nakamura et al., 2006). Advantages 
of these models, however, include allowing precise areas of pathogenesis to be studies and 
presenting with symptoms ranging from insulin resistance to reduced pancreatic β-cell mass 
(Islam and Loots, 2009). The disadvantages associated with these models are that they 
require high levels of maintenance and thus are high in cost. However, amongst researchers 
particularly in developing countries, these models are not widely available (Nakamura et al., 
2006). 
There are several knock-out gene models that exist. These models strive to delete critical 
genes, that without them, diabetic symptoms arise. For instance, animals lacking pancreatic 
duodenal homeobox factor 1 (Pdx-1) lack the essential transcription factor that is required for 
normal pancreatic development (Masiello, 2006). It plays an important role in pancreatic β-
cell differentiation and regulation of critical pancreatic β-cell genes such as those for insulin 
and glucokinase. This results in congenital diabetes, often associated with maturity onset 
diabetes in young adults (MODY) as well as typical T2D (Masiello, 2006). This is a typical 
feature of the Zucker Diabetic Fatty (ZDF) rat (Chen and Wang, 2005). The Zucker diabetic 
fatty rat was developed from a diabetic trait originating from Zucker rats in the USA between 
1974 - 1975. Animals with a diabetic lineage were then identified, leading to the development 
of a Zucker Diabetic Fatty rat inbred line being developed in 1985. It was only in 1991 that 
this model was developed as a genetic model for the study of diabetes (Chen and Wang, 
2005). This rat also contains a genetic defect in the leptin receptor and hence the rats develop 
extreme obesity (Chen and Wang, 2005; Masiello, 2006), hyperglycemia and hyperlipidemia 
(Chen and Wang, 2005; Peterson et al., 1990). These are known as fa/fa rats as they are 
homozygous for non-functional leptin receptors. Rats that are homozygous dominant (+/+) in 
nature and heterozygous (fa/+) remain lean and normoglycaemic. 
The obesity seen in fa/fa rats leads to insulin resistance, however these rats can compensate 
through an increase in pancreatic β-cell mass leading to increased insulin secretion (Masiello, 
2006). This model has proved to be highly advantageous for the study of T2D, as it allows for 
the progressive induction of the prediabetic state through to the diabetic state. Hyperglycemia 
is developed within 7 weeks of age, and by 12 weeks, all obese rats are fully diabetic (Chen 
and Wang, 2005). In addition, GLUT-4, the protein responsible for insulin-stimulated glucose 
18 
 
transport into skeletal muscle and adipose tissue (Patti and Kahn, 1996), is diminished by up 
to 55% in this model (Slieker et al., 1992).  
Other popular rodent model used for diabetic studies is the Otsuka Long-Evans Tokushima 
Fatty Rat (OLETF). This model was developed in 1984 and displayed characteristics of 
polyuria, polyphagia and polydipsia. Other characteristics include mild obesity and unique to 
this model is the delayed onset of hyperglycemia with its induction being noted only after 18 
weeks of age. This model displays a chronic occurrence of the disease state and hence is ideal 
for long term studies involving therapeutic drug intervention trials (Kawano et al., 1994). The 
basis for this model relies on the knockout of several recessive genes. One such gene is the 
cholecystokinin A (CCK-A) receptor gene, resulting in a diminished ability to determine 
satiety after meal consumption, leading to increases in meal size and later, obesity. Gene 
deficits also exist in the hypothalamus signaling pathways of neuropeptide Y (Bi and Moran, 
2002). Hypertriglyceridemia and decreased GLUT-4 receptors also contribute to the 
heterogeneity of the diabetic pathogenesis of these animals (Chen and Wang, 2005).  
1.6.2 Experimentally induced rodent models of T2D 
Non-spontaneous or non-genetic models are so-named as they make use of rodent strains that 
under normal conditions are not diabetic (Islam and Loots, 2009). They are much cheaper in 
cost compared to genetic diabetic strains and are far more widely available to researchers 
worldwide. Experimentally induced models are further subdivided into the following 
categories: those induced by chemical means and those that involve dietary manipulation and 
some include a combination of these two. Besides the cost factor, these models have become 
highly popular in recent years due to the resemblance of the pathogenesis to the biochemical 
profile of diabetic humans, although no one single model clearly shows all pathogeneses and 
symptoms of T2D. However, in recent years, rodent model development has come a long 
way to produce models that resemble the two major pathogeneses of T2D – these being 
firstly insulin resistance and secondly, overtime, the development of partial pancreatic β-cell 
dysfunction.  
1.6.3 Diet induced rodent models of T2D 
1.6.3.1 Fat fed models 
The most commonly used fat fed mouse model is the Diet Induced Obese (DIO) model using 
male C57BL/6J mice. The development of obesity is subjective to the amount of fat added to 
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the diet, with high fat diets used to induce obesity, whilst low fat diets are unable to induce 
obesity. An important consideration when using fat fed rodents to induce insulin resistance is 
the initiation of fat feeding in diets at a young age between 6-8 weeks, as this has been shown 
to be most effective to develop obesity (Reuter, 2007). These high fat fed male C57BL/6J 
mice are typically fed a diet containing 40-60% calories from fat, approximately 8 times 
higher fat content than that of control mice for 8-16 weeks, although diabetic features can be 
noted after just 4 weeks. The longer duration of fat-feeding enhances the features of insulin 
resistance, impaired glucose tolerance revealing elevated serum insulin and glucose, 
abnormal lipid profiling and hyperglycemia in a mild to modest form; the degree to which is 
dependent on the duration of fat feeding and the type of fat (Reuter, 2007; Winzel and Ahrén, 
2004). Pancreatic islet dysfunction is also noted in this model, which is an essential 
pathogenesis for T2D (Reuter, 2007). The DIO rat model most popularly uses outbred 
Sprague-Dawley rats as it has remarkable sensitivity to high fat diets to induce insulin 
resistance and diabetes as opposed to other rat strains (Chang et al., 1990; Reuter, 2007). 
Overtime symptoms of hypertriglyceridemia, hyperglycemia and hyperinsulinemia develop, 
leading to T2D. The major disadvantage of this model is the long duration of time required to 
induce insulin resistance and T2D (Srinivasan and Ramarao 2007), which is not suitable for 
many researchers, as this increases the cost of the experiment.  
1.6.3.2 Fructose fed rodents 
Research indicates that palatability of diets is an important factor in dietary choices, however 
sweet-tasting diets such as high fructose diets enhancing polyphagia and weight gain leading 
to obesity and insulin resistance (Gerrits and Tsalikian, 1993). Fructose-fed rats have drawn 
many associations to the typical American diet which constitutes approximately 10% of the 
dietary energy intake primarily from artificial sweeteners, soda drinks and their content of 
high fructose corn syrup (Benado et al., 2004). Fructose fed rat models target the diabetic 
profile at the lipid level. Hyperlipidemia is directly linked to the development of insulin 
resistance, the first major pathogenesis of T2D (Barnes et al., 2009; Trujillo et al., 2006). 
Research indicates that fructose is more hyperlipidemic than both glucose and starch due to 
its unique metabolism (Benado et al., 2004). High-fructose diets have been shown to 
significantly increase total cholesterol levels through increases in very-low-density 
lipoprotein (VLDL) and low-density lipoprotein (LDL) in rats.  
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Zavaroni (1980) and Tobey (1982) first demonstrated that fructose feeding in rats induced 
symptoms of hypertriglyceridemia, hyperinsulinemia and insulin resistance. To develop these 
pathogeneses, calorie intake in diets contained between 35-72% fructose or 10-15% fructose 
solutions in drinking water (Dai et al., 1994) ad libitum for 2-12 weeks. They demonstrated 
that rats fed a drinking solution of 5-10% fructose showed dose-dependent increases in fluid 
intake, as commonly seen in type 2 diabetics as polydipsia. Furthermore over the 14 week 
period, these rats experienced progressive weight gain. Their experiment also revealed 
feeding a 10% fructose solution (the equivalent of approximately 52.5% calories in a diet) in 
drinking water for 1 week or more was the most suitable model for developing a common 
secondary complication of T2D known as hypertension with increases in systolic blood 
pressure of 20-25mmHg (Dai et al., 1994).  
In a study conducted by Benado et al. (2004), varying concentrations of fructose were 
analysed for their effects on lipid levels in normal rats. Their diet consisted of both fat and 
carbohydrate levels reflecting those typically seen in an average American diet. The fructose 
levels varied between 0%, 10%, 20% and 45% fructose. Although 10% fructose intake is 
deemed equivalent to that of the typical American intake, their results indicated no significant 
difference in total cholesterol, non-HDL cholesterol and triglycerides in 10%-fructose-fed 
rats, yet significant differences in the 20% and 45% groups when compared to the control 
(0% fructose). A significant mean body weight gain was only, however, noted in the 45%-
fructose-fed group. The conclusions drawn indicate that fructose consumption at “normal” 
levels i.e. 10% of energy intake does not produce any adverse effects. However, this was not 
tested in a diabetic rat model. 
1.6.4 Chemically induced rodent models of T2D 
1.6.4.1 Adult Alloxan/Streptozotocin rodents 
Alloxan was the first chemical inducer of T2D used in 1943 by Goldner and Gomori 
(Goldner and Gomori, 1943). Alloxan is a uric acid derivative that selectively destroys 
pancreatic β-cells by oxidative stress mechanisms (Rerup, 1970). Streptozotocin (STZ), on 
the other hand, is a natural antibiotic produced by the bacterial species Streptomyces 
achromogenes (Rees and Alcolado, 2005). It is a structural analogue of N-acetylglucosamine 
that acts as a potent alkylating agent that results in disrupted glucose transport, glucokinase 
activity as well as the induction of multiple DNA strand breaks (Bolzan and Bianchi, 2002). 
Various combinations over the decades have been used to develop models for diabetic 
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research, including single high dose STZ injection, multiple low dose STZ injections or in 
combination with high fat diets. It is, however known that, single high dose STZ injections 
higher than 60 mg/kg body weight (BW) result in massive pancreatic β-cell destruction, more 
characteristic of T1D, whereas low dose STZ injections between 40-55 mg/kg BW cause only 
partial impairment to insulin secretory mechanisms seen in T2D (Srinivasan et al., 2005). 
Dosages lower than 35 mg/kg BW in rats fed a normal commercial diet fail to elicit any 
hyperglycaemic effect (Srinivasan et al., 2005). These compounds can be injected either 
intravenously (i.v.) or intraperitoneally (i.p) at dose concentrations between 35-65 mg/kg BW 
STZ in rats, 100-200 mg/kg BW STZ in mice and in the case of alloxan, 40-200 mg/kg BW 
in rats and 50-200 mg/kg BW in mice (Islam and Loots, 2009).  
1.6.4.2 Neonatal Alloxan/Streptozotocin rodents 
Neonatal alloxan and STZ diabetic models have been employed since the mid 1970’s. A 
decade thereafter, several attempts at refining this model have been made, most successfully 
using doses of STZ between 25 mg/kg BW but less than 50 mg/kg BW in male spontaneously 
hypertensive rats (SHR) (Iwase et al., 1986). In these models, STZ is most commonly 
delivered intraperitoneally to neonatal rats 2 days after birth. Initially until the 4th week, non-
fasting blood glucose levels appear normal to moderately hyperglycaemic. As adulthood 
approaches, hyperglycemia progressively develops, leading to adult-onset T2D (Giddings et 
al., 1985). Important to note are the discrepancies of these models when using different 
rodent strains. Two days old male Wistar rats have been shown to develop diabetes only 
when injected with significantly higher doses of STZ (90 mg/kg BW i.p) (Shinde and Goyal, 
2003), yet Fischer 344 rats developed a stable  and optimal diabetic state when injected 
intraperitoneally at a dose of 80 mg/kg BW. In both adult and neonatal alloxan/STZ models, 
features of hyperglycemia and glucose intolerance develop, however many are not validated 
by anti-diabetic drugs and thus limit their suitability as a model for T2D (Islam and Loots, 
2009).  
1.6.4 3 Monosodium glutamate induced models 
Monosodium glutamate (MSG) is a sodium salt of glutamic acid and is frequently used as a 
flavour enhancer (Jinap and Hajeb, 2010). Studies of the effects of subcutaneous injections of 
MSG on neonatal rats began in the 1970’s where the preliminary results showed detrimental 
effects on rat growth, brain and reproductive function as well as impaired glucose tolerance 
(Lengvari, 1977). In the late 90’s numerous studies revealed the development of central 
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obesity and hyperinsulinemia in MSG treated rats (Ribeiro et al., 1997; Morrison et al., 
2007). 
Iwase et al., (1998) reported significantly higher serum triglycerides in 4 mg/kg BW MSG-
treated rats as compared to control rats, however total cholesterol results remained 
statistically insignificant. Fourteen month old female SHR rats that were neonatally treated 
with 4 mg/kg BW MSG were also reported to have significantly elevated glycated 
haemoglobin, mesenteric fat and body weight, serum blood glucose and insulin as well as 
elevated systolic blood pressure. 
Nagata et al., (2006) developed a novel ICR mouse model for T2D induced by MSG. 
Subcutaneous MSG injections (2 mg/kg BW) were delivered on the day of birth until the 4th 
day of age in both male and female mice, whilst normal saline was injected accordingly to 
control mice. Their results revealed a significantly higher body weight in both sexes 
compared to the respective controls after 7 weeks of age, however no significant differences 
were noted between food and fluid intake compared to the control groups, indicating the 
absence of polyphagia and polydipsia and concluding that obesity was not caused through 
polyphagia. These two characteristic features, however, are common symptoms of the 
diabetic condition. Male-MSG-treated mice developed glucosuria after 8 weeks, whilst 
females only developed this symptom after 19 weeks. After 12 weeks of age, the male mice 
demonstrated significantly impaired glucose tolerance and insulin resistance indicating a 
diabetic state. Furthermore the male mice demonstrated an abnormal liver enzyme profile, 
which is indicative of hepatic insulin resistance. Disadvantageously, this model developed 
small liver tumours, which could interfere in the interpretation of results when being used as 
a model for T2D. In the development of this model it was also shown that male mice serve as 
a better model as the females appear to be less susceptible to the detrimental effects of MSG. 
Morrison et al., (2007) injected MSG at a dose of 4g/kg BW intraperitoneally from the first 
day of birth until the 7th day. Their results revealed central obesity in the MSG-treated rats as 
well as all rats over the age of 65 weeks having developed cataracts, a common complication 
of T2D. After 32 weeks of age, no significant differences were noted in glucose tolerance 
tests compared to control rats, however differences were noted after 65 weeks between the 
two groups. Whilst this comparatively new model for T2D offers both the major and minor 
pathogeneses of T2D, it is limited in its use as it has not been validated by anti-diabetic drugs 
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and similarly to the intrauterine growth retardation (IUGR) model, the long induction time of 
the diabetic state is unfavourable (Islam and Loots, 2009).  
1.6.5 Combined rodent models of T2D 
1.6.5.1 Fat-fed streptozotocin rodents 
Diet induced diabetes was first described in 1947 by Houssay and Martinez.  The fat-fed 
STZ-injected rat makes use of dietary manipulation to induce insulin resistance and STZ to 
induce partial pancreatic β-cell dysfunction. This model has a major advantage over genetic 
models in that it replicates the natural disease history and pattern as well as producing several 
characteristics that parallel the human condition (Chen and Wang 2005). In 2000, Reed et al. 
were the first to develop the fat-fed-STZ-injected rat drawing on the rationale that Sprague-
Dawley rats develop both insulin resistance and hyperinsulinemia, but not hyperglycemia 
when fed a high-fat diet. The use of STZ caused a subsequent decline in plasma insulin 
concentrations leading to hyperglycemia and T2D. These rats were fed a diet consisting of 
40% fat, 41% carbohydrate and 18% protein which was continued throughout the entire 
experimental period. After 2 weeks of feeding, the rats were injected with 50 mg/kg BW 
STZ. 
A similar, but modified attempt at this model of T2D was done by Srinivasan et al. (2005). In 
their modifications, the high-fat diet contained 58% fat, 17% carbohydrates and 25% protein 
and was similarly supplied ad libitum throughout the entire experimental period. After the 2 
week period of dietary manipulation, the rats received a 35 mg/kg BW injection 
intraperitoneally of STZ. This resulted in frank hyperglycemia, significantly elevated total 
serum cholesterol and serum triglycerides. Significantly decreased serum insulin compared to 
rats fed only a high-fat diet was also noted, yet no significant differences were noted between 
rats injected with STZ and fed a normal rat pellet diet. Advantageously this model was also 
sensitive to anti-diabetic drugs confirming its suitability as a model for T2D. Whilst it 
appears to be a good choice for use as a rodent model for T2D, several critical biochemical 
parameters have not been tested, including liver function enzymes, liver glycogen, pancreatic 
histopathology and serum creatinine (a measure of kidney function). Although the model 
remained stable over a 10 week experimental period, further biochemical data are required to 
enhance its suitability to long-term studies of diabetic complications such as nephropathy, 
neuropathy, retinopathy and cardiomyopathy. 
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Further modifications have been reported by Zhang et al. in 2008 that utilized a combination 
high-fat diet with multiple low-dose STZ injections. Their high-fat diet consisted of 22% fat, 
48% carbohydrates and 20% protein. The rats were intraperitonteally injected with STZ twice 
at a dose of 30 mg/kg BW, with a 1 week period between injections. The high-fat-fed diet 
was supplied for a duration of 4 weeks. In contrast to Srinivasan’s model, this model 
demonstrated both lower total serum cholesterol and serum triglycerides compared to the 
high-fat-diet control group, and only demonstrated significantly elevated fasting blood 
glucose compared to the normal rat pellet fed controls.  
1.6.5.2 Streptozotocin-nicotinamide models 
Nicotinamide (NA) is the amide derivative of nicotinic acid and is used as a therapeutic agent 
in diabetic research. It is a potent scavenger of free radicals and provides a component of the 
coenzyme nicotinamide adenine dinucleotide (NAD). Nicotinamide (NA) in high doses has 
been noted to have a protective function on pancreatic β-cell survival against both exogenous 
toxic agents as well as from immune responses (Knip et al., 2000). This can diminish the 
toxic effects exerted by STZ on pancreatic β-cells, with extremely high doses (350 mg/kg 
bw) having shown to fully prevent STZ-induced damage (Masiello et al., 1998). STZ induces 
DNA damage in pancreatic β-cells and activates the enzyme poly(ADP-ribose) synthetase. 
Nicotinamide (NA) inhibits this enzyme, thereby reducing apoptotic levels within the 
damaged pancreatic β-cells, thereby promoting pancreatic β-cell survival (Masiello et al., 
1998). 
The STZ-NA model was originally developed by Masiello et al. in 1998 and later, Nakamura 
et al. (2006) adapted this to resemble a non-obese non-genetic model of T2D in mice. 
Westernised diets tend to be higher in calorie content and thus pose a new set of problems in 
terms of metabolic disturbances. It is widely known that T2D patients show signs of insulin 
resistance, yet many non-obese patients of T2D are showing signs of inadequate insulin 
secretion, as opposed to insulin resistance (Nakamura et al., 2006). The STZ-NA models can 
therefore provide many similarities to type 2 diabetics that are non-obese (Nakamura et al., 
2006). This model is characterized by normal weight gain and insulin secretion despite a 
slightly altered ability to produce insulin from pancreatic β-cells. Furthermore it shows 
slightly altered fasting blood glucose levels and only mild glucose intolerance (Nakamura et 
al., 2006). This model is advantageous in comparison to other non-genetic T2D models as it 
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can be quickly developed in a 5 week time period thus also allowing for experimental costs to 
be reduced (Nakamura et al., 2006).    
The basis for this model relies on the theory that STZ-induced DNA damage stimulates DNA 
repairs mechanisms that consume large quantities of nicotinamide dinucleotide (NAD). This 
can be supplemented by consumption of NA. The NA serves as a partial protector against 
excessive pancreatic β-cell damage caused by STZ. Masiello et al. (1998) developed this 
model using a dose of 230 mg/kg BW NA intraperitoneally delivered 15 minutes prior to an 
intraperitoneal STZ injection at a dose of 65 mg/kg BW in 3 month old male Wistar rats. This 
model showed features of hyperglycemia in the non-fasted state, abnormal glucose tolerance 
and insulin responses as well as a 40% preservation of pancreatic insulin stores. In the latter 
model developed by Nakamura et al., male C57BL/6J mice at 5-6 weeks of age were used 
and injected twice with STZ intraperitoneally at a dose of 100 mg/kg BW at day 0 and 2 of 
the experiment along with 240 mg/kg BW NA 15 minutes prior to each STZ injection. To 
this combination they also investigated the effects of a high-fat diet on this model. The high-
fat-fed-240 mg/kg BW NA with 100 mg/kg BW STZ model revealed significantly elevated 
total cholesterol, triglycerides and HDL cholesterol compared to normal pellet diet-fed mice. 
The two variations also demonstrated significantly higher plasma glucose concentrations 
compared to normal mice. This model is advantageous as it resembles closely the diabetic 
pattern seen in East Asian diabetic patients, a large percentage of which are non-obese. Both 
models by Masiello et al. (1998) and Nakamura et al. (2006) were validated by anti-diabetic 
drugs and thus are suitable for drug screening and pharmacological studies, however they are 
only applicable for non-obese T2D.  
1.6.6 Surgical rodent models of T2D 
1.6.6.1 Partial pancreatectomized models  
As a means to avoid liver and kidney damaged induced by alloxan, Pauls and Bancroft (1949) 
developed a new method to induce T2D in mice through partial pancreatectomy. In 1983, 
Bonner-Weir et al. aimed to study the consequences of reduced pancreatic β-cell mass in rats 
through removal of 85-90% of the pancreas. These animals displayed moderate 
hyperglycemia from day 4 post-surgery and was maintained for a further 6 week period. 
During this 6 week period, no significant differences were noted in serum insulin or body 
weight compared to control groups, however, after 7 weeks they had a normal fasting blood 
glucose and insulin concentration, and only became hyperglycaemic postprandially or after 
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an intraperitoneal glucose tolerance test (IPGTT). A major limitation of this model is the 
regeneration of the remnant pancreas, although for some researchers, studies into the adaptive 
mechanisms of pancreatic β-cells may be required, for which this model is particularly useful 
(Masiello, 2006). Srinivasan and Ramarao (2007) noted the advantages of this model being 
the resemblance of T2D through reduced pancreatic β-cell mass and that this model avoids 
any cytotoxic effect of chemical-inducers of T2D on other body organs. A more stable form 
of diabetes can be developed through the combination of partial pancreatectomy with 
chemical inducers such as STZ and alloxan. One such model, makes use of a 50% 
pancreatectomy in combination with 350 mg/kg BW NA prior to and after intraperitoneal 
injection of 200 mg/kg BW STZ in BALB/c mice. This model demonstrated stable and 
significantly elevated fasting blood glucose with reduced serum insulin yet a drastic loss in 
body weight, which is usually seen in T1D (Kurup and Bhonde, 2000). The overall 
disadvantage of this model is the advanced technical and surgical skills required for such 
studies. A well-equipped surgical laboratory is required, as this is a major surgery and the 
risk of infection in the animals is high. The animals must be supplied with post-surgical 
antibiotics as well as administration of pancreatic enzymes (Fröde and Medeiros, 2008). A 
potential disadvantage of this model is the development of glucose insensitivity, a feature not 
seen in human T2D (Masiello et al., 1998). Another disadvantage may be the occurrence of 
digestive problems due to the excision of exocrine portions of the pancreas leading to a 
deficiency in amylase enzymes (Srinivasan and Ramarao, 2007). 
1.6.6.2 Intrauterine growth retardation models 
Intrauterine growth retardation (IUGR) is the low-birth weight of infants due to the limited 
availability of nutrients to the fetus during gestation and is a relatively common complication 
of pregnancies (Simmons et al., 2001; Vuguin et al., 2004). Barker et al. (1993) were the first 
to speculate that IUGR was linked to the development of disease later in life, specifically the 
development of obesity, hypertension and T2D. Nutrient deficits to the fetus result in 
modifications to the gene expression and functionality of cells within the pancreas, liver and 
muscle (Peterside et al., 2003). This is confirmed by earlier work by Hales et al. in 1991 who 
demonstrated that poor fetal and neonatal growth is directly linked to T2D in adulthood. 
IUGR causes significant reductions in pancreatic β-cell mass in neonates, which are never 
recovered in adulthood, resulting in impaired glucose tolerance and can lead to the 
development of T2D. Advantageously, these animals follow the natural pattern of disease by 
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developing insulin resistance as an early feature in life and later developing hyperglycemia 
and subsequent pancreatic β-cell dysfunction (Simmons et al., 2001).  
In 2001, Simmons et al. developed an IUGR rodent model through bilateral uterine artery 
ligation such that blood flow to the fetus is not fully diminished but rather reflecting the 
human complication seen in some pregnancies. After 19 days of gestation, these rats were 
anesthetized with xylazine (8 mg/kg BW) and ketamine (40 mg/kg BW) intraperitoneally and 
both uterine arteries were cut. Neonatally these rats displayed decreases in insulin compared 
to controls and significantly decreased body mass. However, by week 26, IUGR rats were 
obese in nature, having a significantly higher fat pad mass around the body compared to the 
control rats. 1 week after birth, these rats displayed no significant differences in fasting blood 
glucose or insulin, however after week 7, there were significant differences in both fasting 
blood glucose and insulin compared to the control, indicating mild hyperglycemia and 
hyperinsulinemia. However, significantly increased insulin levels were sustained only until 
week 15, after which they remained non-significantly different from the control, having 
demonstrated a decline in insulin secretion. On the other hand, increases in fasting blood 
glucose seen in the IUGR group continued to rise, even after 26 weeks, having fasting blood 
glucose higher than 200 mg/dl, indicating a state of T2D. Studies done by Vuguin et al., 
(2004) demonstrated that IUGR permanently alters hepatic glucose metabolism through 
oxidative stress mechanisms in the fetal development, thus occurring prior to the onset of 
obesity and hyperglycemia, thus representing an early defect, similar to insulin resistance 
seen in humans.  
The major advantages of this model are the successful induction of insulin resistance, 
hyperglycemia, hyperinsulinemia, obesity and reduced pancreatic β-cell mass. However, 
many additional diabetic parameters including lipid profiling, liver and kidney functioning 
and responses to anti-diabetic agents have not yet been reported and hence remain unknown, 
thus compromising its suitability as a model for T2D on the whole. Moreover, the surgical 
ligation of uterine arteries requires advanced technical skills and the development of T2D is 
only seen after 3 months of age (Simmons et al., 2001, Vuguin et al., 2004) thus requiring a 
long induction period which may not be suitable for some researchers. Further investigations 
are required to enhance the suitability of this model, however, the literature reported thus far, 




1.7 Statement of purpose, problem identification and aim of study  
As indicated by the extensive research above, several animal models are available to date. 
Some include the use of large animals, such as pigs, dogs, monkeys and other primates 
(Srinivasan and Ramarao, 2007). These are useful for their similar size to humans and 
similarity to the disease phenotypes. However, the development of the diseased state in these 
animals requires a long time frame, making data collection difficult and husbandry expenses 
high (Daneshgari et al., 2009). Smaller animals such as rodents are more frequently used for 
such research, due to their short generation time (Chen and Wang, 2005), smaller size, ease 
of handling due to their tranquil nature and maintenance as well as their cheaper costs (Islam 
and Loots, 2009).  
Although models for T2D have been plentiful in the last few decades, however none are 
without limitations. As described above, two major types of models exist for such research: 
genetic models (genetically induced spontaneous models) and non-genetic models 
(experimentally induced non-spontaneous models). Genetic animal models include inbred 
strains as well as knock-out and transgenic mice (Reuter, 2007). However, there are several 
limitations to this approach as only 40% of patients presenting with T2D diabetes have a 
family history of this disorder. In addition, T2D sufferers tend to have a “polygenic mode of 
inheritance” as opposed to single-gene defects developed in genetic animal models of T2D 
(Reuter, 2007). Highly selective inbred strains also fail to account for the large heterogeneity 
seen in the human population suffering with T2D. Moreover, these models are expensive, not 
easily accessible, and tend to show features more typical of T1D as opposed to T2D 
(Srinivasan et al., 2005).  Non-genetic dietary-induced T2D models thus provide a more 
heterogenous approach to investigate the pathology of T2D, however most of these models 
do not present with closely accurate correlations to the human clinical condition (Masiello et 
al., 1998). Many of the non-genetic models as well as genetic models of T2D fail to develop 
heterogeneous symptoms seen in T2D patients. Non-genetic models often more closely 
resemble T1D, whereas genetic models exhibit single gene defects, thereby failing to 
demonstrate heterogeneity of symptoms seen in patients with T2D (Winzel and Ahrén, 2004). 
There is therefore an urgent need to develop and establish better models for T2D by either 
adjusting or altering existing models, developing novel methodologies or through a 
combination of the two (Zhang et al., 2008).  
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The aim of this study was, therefore, to develop a novel, alternative non-genetic model, 
which will be inexpensive and easy to develop, and will be appropriate to generate all major 
pathological features of T2D. In addition, it is aimed that the model will be suitable for 
pharmacological screening and acute studies that can be used in developing countries that 




CHAPTER 2 Fructose-fed-streptozotocin-injected rat model 
2.1 Model development background 
Animal models in diabetes research are very common where rats are the first choice of use, 
comprising over 85% of these models (US Department of Agriculture, 1989). Although 
genetic models provide a better pathogenesis for the disease, non-genetic models, are far 
more cost-effective, widely available and easy to develop diabetes with minimal research 
facilities, which is particularly useful in developing countries where funds and resources may 
be limited (Islam and Loots, 2009). The major disadvantages of the non-genetic type 2 
diabetes (T2D) models include resembling the pathogenesis of Type 1 diabetes (T1D) more 
closely than the T2D. Furthermore, to date, many models have not been validated by anti-
diabetic drugs thus their use and suitability for pharmacological screening is unknown (Islam 
and Loots, 2009). Pharmacological screening is an important aspect of T2D model 
development as T1D models would remain insensitive to T2D drugs. This is due to major 
mechanistic differences as many T2D drugs aim to increase insulin sensitivity e.g. metformin 
or enhance insulin secretion e.g. glibenclamide. T1D models will not respond to these drugs 
due to an absolute insulin deficiency arising from the autoimmune destruction of pancreatic 
ß-cells. Besides the disadvantage related to non-similarity of disease pathogenesis, many of 
the existing diet-induced models, such as fat-fed and fructose-fed models, require a long 
diabetes induction time, which increases the experimental cost of research (Srinivasan et al., 
2005, Reuter, 2007).  
Successful models of T2D are required to display the two major pathogeneses of T2D: a 
progressive decline in insulin action (insulin resistance), followed by the inability of 
pancreatic β-cells to compensate for insulin resistance (pancreatic β-cell dysfunction) 
(Srinivasan et al., 2005). The pathogenesis of diabetes in animal models is most likely similar 
to the pathogenesis in humans, however the dose and type of inducers and the composition of 
diets largely affect the success of the induction of T2D in experimental animals. Hence, many 
factors and situations need to be considered in order to develop an authentic animal model of 
T2D. Literature has shown that low fat diets are not enough to induce insulin resistance but 
very high fat diets in combination with a streptozotocin (STZ) injection may cause severe 
pancreatic β-cell damage as well as permanent insulin resistance (Reed et al., 2000).  
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On the other hand, lower doses of STZ such as 40 mg/kg BW or less via intraperitoneal 
injections have been shown to be ineffective in inducing T2D whilst more than 50 mg/kg BW 
is usually used to induce the pathogenesis of T1D in rats (Katsumata et al., 1992, Islam and 
Choi, 2007). Furthermore, while being used extensively in the development of diabetes, STZ 
is unable to induce insulin resistance directly, rather, results in hyperglycemia from direct 
pancreatic β-cell damage (Srinivasan et al., 2005). However, the induction of insulin 
resistance through fructose-feeding in animals has been employed previously (Hininger-
Favier et al., 2009). Fructose has been supplied ad libitum either in drinking water or with 
diets with a concentration of 10-15% for a short or longer period to induce insulin resistance 
or T2D respectively in experimental animals (Dai et al., 1994). Unfortunately the induction 
of insulin resistance as well as T2D only by fructose-feeding requires several weeks which 
increases the cost of study. It was thus hypothesised that the combination of fructose-feeding 
for a shorter period of time and a lower dose of STZ injection may induce all major 
pathogeneses of T2D in rats. 
2.2 Materials and method 
2.2.1 Reagents and materials 
Streptozotocin (STZ) (>98%) (Sigma-Aldrich) was purchased from Capital Lab Supplies cc. 
Durban, South Africa.  Glucostrips, and Fructose (Nature’s Choice™ Wholefood specialists, 
Meyerton, South Africa 1960) were purchased from a local pharmacy. Glibenclamide 
(Pharmacare Ltd.) and Metformin (Austell Laboratories Pvt. Ltd.) were purchased from a local 
pharmaceutical company (Pharmed Ltd., Durban, South Africa). A glucometer (GlucoPlus Inc, 
Quebec, Canada, measuring up to 600 mg/dl) was used for measuring fasting and non-fasting 
blood glucose levels. Serum analysis was conducted using an Automated Chemistry Analyzer 
(Labmax Plenno, Labtest, Lagon-Santa, Brazil) according to manufacturer’s instructions. 
2.2.2 Animals 
Thirty-six (6 weeks old) male Sprague-Dawley rats were procured from the Biomedical 
Resource Unit (BRU) at Westville Campus from the University of KwaZulu-Natal, South 
Africa. Animals were randomly subdivided into 6 groups, each containing 6 rats each as 
follows: Normal Control (NC), Diabetic/Streptozotocin control (STZ), Fructose-10% 
(FR10+STZ), Fructose-20% (FR20+STZ), Fructose-30% (FR30+STZ) and Fructose-40% 
(FR40+STZ) with a mean similar weight of 190.56 g ± 23.60g. Two rats per poly-carbonated 
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cage were housed in a temperature and humidity controlled room with a 12 hour light-dark 
cycle. The rats were fed a commercially available rat chow diet ad libitum throughout the 
entire 11 week experimental period. Control groups were supplied with normal drinking 
water ad libitum whilst FR10+STZ, FR20+STZ, FR30+STZ and FR40+STZ were supplied 
with 10%, 20%, 30% and 40% fructose solutions respectively for 2 weeks only to induce 
insulin resistance. Hereafter they were supplied with normal drinking water for the remainder 
of the experiment. The animals were maintained according to the rules and regulations of the 
University of KwaZulu-Natal (UKZN) Animal Ethics Committee (Ethical approval number: 
076/10/Animal).  
2.2.3 Induction of diabetes 
All animals received a regular chow diet whilst FR10+STZ, FR20+STZ, FR30+STZ and 
FR40+STZ additionally received a 10%, 20%, 30% and 40% D-Fructose respectively in 
drinking water for 2 weeks. Hereafter, STZ was dissolved in citrate buffer (pH 4.4). The 
solution was then filtered through a sterilized 0.45 millipore filter. After 2 weeks of dietary 
manipulation, diabetes was induced in all groups, except the NC group by a single 
intraperitoneal injection of STZ (40 mg/kg BW) whilst the NC group received a vehicle 
citrate buffer (pH 4.4) injection only. 
Fasting and non-fasting blood glucose levels of all animals were measured 1 week after STZ 
injection. Blood was taken from rat tail veins using a 25G needle and blood glucose was 
measured using a portable glucometer (GlucoPlus Inc, Quebec, Canada). Animals with 
fasting blood glucose (FBG) level > 200 mg/dl or non-fasting blood glucose (NFBG) level > 
300 mg/dl were considered diabetic. FBG levels were measured weekly throughout the 
experimental period until 1 week after STZ injection (Week 4).  Hereafter NFBG levels were 
measured (Week 5-12) weekly. The rats were firstly fasted for a 12 hour period, after which 
food was returned ad libitum for 3 hours and then subsequent NFBG was measured. During 
the fasted period, all groups received normal drinking water and the amount consumed after 
the 12 hour period was recorded. During the 3 hour feeding period prior to NFBG 
measurements, groups consuming fructose solutions had these returned, whilst the controls 





2.2.3.1 Food and fluid intake, body weight and exclusion of animals 
 Daily food and fluid intake were monitored and weekly body weight changes were measured 
during the entire experimental period. Three weeks after the STZ injection, the severity of 
diabetes was significantly higher in the FR20+STZ, FR30+STZ and FR40+STZ groups and 
some of the animals from these groups were dead due to severe hyperglycemia. Therefore, 
the rest of the animals of these groups were excluded from the study and the remaining 
experiment was continued with NC, STZ and FR10+STZ groups. None of the animals were 
dead from these groups.  
2.2.4 Oral glucose tolerance test 
After an overnight fast (12 hours), rats were orally dosed with a D-glucose solution (2.0 g/kg 
BW) at week 6 of the experimental period. Glucose concentrations were subsequently 
measured by blood collection from the tail veins at 0 (just prior to oral glucose dosing), 30, 
60, 90, and 120 minutes after oral dosing and blood glucose levels monitored with a 
glucometer.  
2.2.5 Effect of anti-diabetic drugs on fructose-fed-streptozotocin-injected rats 
The validity and suitability of the fructose-fed-STZ-injected rat model for pharmacological 
screening was determined by performing several anti-diabetic drug response tests. Two 
established and commonly employed, but mechanistically different, anti-diabetic drugs were 
used, namely insulin secretogogues such as metformin (biguanide) and glibenclamide 
(sulfonylurea). These tests were performed at week 7 and 9 of the experimental period 
respectively. Each group received a single oral dose of metformin (500 mg/kg BW) dissolved 
in 1% Na-CMC or a single dose of glibenclamide (5 mg/kg BW) dissolved in 1% Sodium 
carboxymethylcellulose (Na-CMC). For the glibenclamide test, the blood glucose 
concentration of each animal was measured at 0 and 180 minutes post oral administration of 
the drug. For the metformin test, the blood glucose concentration of each animal was 
measured at 0, 30, 60, 120 and 180 minutes post oral ingestion of the drug. A one week drug 
wash out period (week 8) was required between anti-diabetic drug response tests to ensure no 





2.2.6 Collection of blood, liver, pancreas, kidneys and heart 
At the end of the experimental period animals were fasted for 14 hours prior to euthanasia by 
halothane anaesthesia. Animals were weighed before euthanasia after which blood, liver, 
heart, kidneys and pancreas were collected. Blood was collected through cardiac puncture 
using a 21G needle and fasting blood glucose levels were immediately measured using a 
portable glucometer. Blood samples were subsequently placed in heparin tubes and allowed 
to coagulate on ice for approximately 3 hours and then centrifuged at 3000rpm for 15 
minutes. Hereafter, serum was separated into labelled microtubes and stored at -30˚C for 
further analysis. Liver, kidney and heart samples were washed in cold 0.9% saline solution, 
wiped dry with filter paper, weighed on an analytical balance and preserved at -30˚C for 
further analysis. Part of the pancreas sample was immediately fixed in 10% neutral buffered 
formalin solution for histopathological examinations, which was replaced weekly during the 
entire preservation period. The remainder of the pancreas was preserved at -30˚C for further 
analysis.  
2.2.7 Analytical methods 
Liver glycogen concentration was measured photometrically by using the phenol-sulphuric 
acid method as described by Lo et al. (1970). Serum insulin was analyzed using an ultra 
sensitive rat insulin ELISA kit (Mercodia AB, Uppsala, Sweden) using a multi plate ELISA 
reader (Biorad-680, BIORAD Ltd., Japan). HOMA-IR and HOMA-beta scores were 
calculated using fasting serum insulin and FBG concentrations at the end of the experimental 
period according to the following formula: 
HOMA-IR     = [Insulin (U/L) x Blood glucose (mmol/L)]/ 22.5 
HOMA-beta = [20 x Insulin (U/L)] / [Blood glucose (mmol/L) – 3.5] 
Conversion factor: Insulin (1U/L = 7.174pMol/L) and Blood glucose (1mmol/L = 18 mg/dl) 
Serum lipid profiles, serum creatinine and liver function enzymes (AST and ALT) were 
measured using an automated chemistry analyzer (Labmax Plenno, Labtest, Brazil). Total 
cholesterol was measured directly in the serum according to the following principle: 
Cholesterol + O2  cholesterol oxidase> Cholest-4-en-one + H2O2. 
H2O2+ phenol + 4-aminoantipyrine  
peroxidase> Quinonemine + 4H2O. 
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Quinonemine is maximally absorbed at 500 nm. The intense red colour generated is directly 
proportional to the cholesterol concentration in the sample. LDL cholesterol was 
quantitatively precipitated after centrifugation. Triglycerides are measured in a similar 
manner to total cholesterol to yield quinonemine. The red colour that is produced is directly 
proportional to triglyceride concentration.  
Creatinine was measured according to the following test principle: 
Creatinine + alkaline picrate −−−→ Creatinine picrate  
This yields an intense red colour. This red colour is directly proportional to the concentration 
of creatinine at 510 nm.  
Liver enzyme ALT was measured according to the following test principle:  
L-Alanine + ketoglutarate  
ALT
> Pyruvate + L-glutamate 
Pyruvate + NADH 
LDH
>  Lactate + NAD 
NADH oxidation at 340 nm is directly proportional to the ALT activity in a sample. AST is 
measured in an almost identical manner: 
L-Aspartate + ketoglutarate 
AST
>  Oxaloacetate + L-glutamate 
Oxaloacetate + NADH 
LDH
>  Lactate+ NAD 
2.2.8 Liver glycogen content 
Liver glycogen content was measured photometrically according to the Phenol-Sulphuric acid 
Method developed by Lo et al., (1970). Liver samples of ≤ 1.0g were measured and placed at 
the bottom of a screw-capped pyrex tube using forceps and then placed on ice. The sample 
was then immersed in 1.5ml of 30% KOH saturated with Na2SO4. This was then placed in a 
boiling water bath for 20-30 minutes. The sample was then removed and allowed to cool on 
ice. 2ml of 95% ethanol was then added and placed on ice for a minimum of 30 minutes. 
Samples were centrifuged at 840 x g (2812 rpm) for 25-30 minutes. The supernatant was 
aspirated and the glycogen precipitate was dissolved in 3.0ml distilled water. 50µl of this 
solution was transferred to a clean test tube containing 450µl distilled water. This was 
performed in duplicate. Glycogen standards were prepared from a stock solution of 1 mg/ml 
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glycogen (Oyster, Type II, SIMGA-ALDRICH, USA) at concentrations of 10, 20, 40, 80, 
160, 320 and 640µg/ml. To both the standards and samples, 0.5ml of 5% phenol was added to 
each test tube, followed by the rapid addition of 2.5ml 96-98% H2 SO4. This was left to stand 
at room temperature for 10 minutes, after which the absorbance was read in a 
spectrophotometer at 490nm. A solution of distilled water served as the blank. The 
concentration of liver glycogen was thereafter calculated from a liver glycogen standard 
curve. This experiment was performed in duplicate. 
2.2.9 Serum insulin analysis 
Rat serum analysis was performed using a Ultrasensitive Rat Insulin ELISA kit from 
Mercodia (Uppsala, Sweden). This kit provides a method for the quantitative determination 
of serum insulin. It makes use of a direct technique whereby 2 monoclonal antibodies act 
against different antigenic sites on the insulin molecule. Insulin contained in the rat serum 
reacts with a peroxidase-conjugated anti-insulin antibody during incubation. The several 
washing steps remove any unbound enzyme-labelled antibodies. The bound conjugate is then 
detected through the reaction with 3,3’,5,5’-tetramethylbenzidine. This reaction is then 
stopped by the addition of sulphuric acid giving rise to a yellow colour that is read 
photometrically at 450nm. This experiment was performed through the development of a 
serum insulin standard curve using 50µl of a range of calibrators from Calibrator 0-7. In 
separate wells, 50µl of serum sample was added after which 50µl of enzyme conjugate was 
added to all wells. This was incubated on a shaker at 700-900rpm for 2 hours at room 
temperature. Hereafter, the solution was aspirated followed by 6 wash steps of 350µl of 21x 
wash buffer. At the last wash step, the plate was inverted and tapped firmly against absorbent 
paper towel. 200µl of Substrate TMB was added to all wells. This was incubated for 30 
minutes in which time a blue solution developed. After 30 minutes, a stop solution comprised 
of acid was added to all wells in 50µl aliquots. This was shaken for 5 seconds to ensure 
adequate mixing of Substrate TMB and the stop solution. The absorbance was read in 
triplicate using a multiplate reader (Biorad-680, BIORAD Ltd., Japan) at 450nm. 
2.2.10 Histopathological examination of pancreatic islets and staining 
Immediately after pancreatic organ collection, a small section of the pancreas was cut and 
placed in a 1ml eppendorf tube containing 10% neutral buffered formalin. The formalin 
solution was changed weekly until tissue processing. For tissue processing, the section of 
pancreas was dehydrated in 2 changes of 70% ethanol for 1 hour each, followed by 1 change 
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in 80% ethanol for 1 hour, 1 change in 90% ethanol for 1 hour and 1 overnight change in 
100% ethanol. The following day, the tissues were cleared in 3 changes of xylene for 1.5 
hours each. The tissue sections were embedded in paraffin wax. The paraffin blocks were 
trimmed to an appropriate size. Sections were cut at 3µm and placed in a water bath at 40-
45ºC. The sections were mounted onto slides and allowed to air-dry overnight. The following 
day, the slides containing the cut sections were deparaffinized in 2 changes of xylene for 5 
and 2 minutes respectively. The slides were rehydrated in 1 change of 100% ethanol for 2 
minutes, 1 change of 90% ethanol for 2 minutes, 1 change of 70% ethanol for 2 minutes, 1 
change of 50% ethanol for 2 minutes and placed in distilled water. The slides were stained for 
5 minutes using hematoxylin as the primary stain, and washed in running tap water. Hereafter 
the slides were stained for 3 minutes in eosin as a counterstain. The slides were then dipped 
in 90-100% ethanol followed by xylene, wiped and coverslipped in DPX mounting agent. 
The slides were then viewed using a light microscope (Olympus CKX41, Olympus, Japan) 
connected to a computer.  
2.2.11 Statistical analysis 
All data are presented as mean ± SD. The data were analyzed by a statistical software 
package (Statview, Version 5.0, Cary, NC, USA) using the Tukey-Kramer multiple range 
post-hoc test and Tukey-Kramer paired T-test. The values were considered significantly 












2.3.1 Daily food intake  
Figure 12 shows the mean food intake (g) per animal per day over the 11 week experimental 
period. Food intake was measured daily at 9 am. FR10+STZ group displayed non-
significantly higher food intake compared to STZ and NC, and similar results were observed 
for STZ compared to NC.  
 
Figure 12: Mean food intake (g) per animal per day over the 11 week experimental 
period. Data are expressed as mean ± SD of 6 animals, where NC: Normal Control, STZ: 



















































2.3.2 Daily fluid intake 
Figure 13 shows the mean fluid intake (ml) per animal per day. The FR10+STZ group reveals 
significantly higher (p < 0.05) fluid intake compared to NC and STZ, whereas no significant 
differences were noted between NC and STZ groups. FR10+STZ group was the only group to 
receive 10% fructose solution in drinking water ad libitum for the initial 2 weeks, and 
hereafter received normal drinking water ad libitum for the remainder of the experiment. NC 
and STZ received normal drinking water ad libitum throughout the entire experimental 
period. 
 
Figure 13: Mean fluid intake (ml) per animal per day over the 11 week experimental 
period. Data are expressed as mean ± SD of 6 animals, where NC: Normal Control, STZ: 
Diabetic Control, FR10+STZ: Fructose 10%+STZ. *p < 0.05 vs. NC and #p < 0.05 vs. STZ 

















































2.3.3 Weekly body weight (BW) gain 
Figure 14 shows the weekly BW gain over the 11 week experimental period. During the first 
3 weeks, no significant differences were noted in BW gain between the animal groups. After 
the injection of STZ, the BW gain of the FR10+STZ group was significantly reduced 
compared to the NC group. Minor weight loss was seen in the STZ and FR10+STZ groups 
one week after the STZ injection, however this is a common effect of STZ and is recovered 
quickly. Weeks 4-11 revealed steady weight gain amongst all animal groups with minor 
weight loss in week 11 due to the fast incurred prior to euthanasia by halothane anaesthesia.  
Figure 14: Mean weekly BW gain over the 11 week experimental period. Data are 
expressed as mean ± SD of 6 animals. *p < 0.05 vs. NC and #p < 0.05 vs. STZ (Tukey-










































2.3.4 Weekly blood glucose 
Figure 15 shows the mean weekly blood glucose levels (mg/dl) throughout the experimental 
period. FBG revealed no significant differences between the animal groups, including the 
week after STZ injection. NFBG on the other hand revealed significantly higher blood 
glucose in the FR10+STZ group compared to both the STZ and NC groups. The STZ group 
also demonstrated significantly higher NFBG compared to the NC group. The STZ group did 
not maintain a NFBG > 300 mg/dl throughout the experimental period, however, the 
FR10+STZ group maintained NFBG between 350-400 mg/dl for the duration of the 
experiment. NFBG > 300 mg/dl was considered as a scale for type 2 diabetes. 
Figure 15: Mean blood glucose (mg/dl) over the 11 week experimental period. Week 0-3 
are indicative of fasting blood glucose (FBG), whilst week 4-11 are indicative of non-fasting 
blood glucose (NFBG). Data are expressed as mean ± SD of 6 animals. *p < 0.05 vs. NC and 













































































2.3.5 Oral glucose tolerance test (OGTT) 
The data for OGTT are displayed below in Figure 16. OGTT is a clinical diagnostic test to 
assess glucose tolerance ability of the body over 2 hours and can determine glucose 
intolerance as well as T2D. All animals were fasted overnight prior to oral dosing after which 
and a 2g/kg BW solution of D-glucose was administered to all rats. The blood glucose of all 
animals was measured at 30 minute time intervals over a 2 hour period. The blood glucose of 
the STZ and FR10+STZ groups were significantly higher than the NC group. The STZ group 
demonstrated a sharp decline in blood glucose after 90 minutes, with a blood glucose level 
below 200 mg/dl after 2 hours. The blood glucose of the FR10+STZ group remained elevated 
over 300 mg/dl almost for the entire 2 hour period. 
 
Figure 16: Oral Glucose Tolerance Test (OGTT) over 2 hours at week 6 of the 11 week 
experimental period. Data are expressed as mean ± SD of 6 animals. *p < 0.05 vs. NC and 













































2.3.6 Effect of anti-diabetic drugs on the FR10+STZ group 
In order to assess and validate the model’s potential and suitability for routine 
pharmacological screening, Figure 17 and 18 showed the effect of two commonly used anti-
diabetic drugs on the FR10+STZ group. In the case of both tests, blood samples from the 
FR10+STZ group were collected from tail veins just prior to drug administration (0 minutes), 
and after 180 minutes. When dosed with metformin, the blood samples were additionally 
collected at 30, 60, 120 and 180 minutes after drug ingestion. In both cases, blood glucose 
was significantly reduced after 180 minutes, and in the case of metformin, significant 
reductions were observed at both 120 and 180 minutes compared to 0 minutes. Glibenclamide 
significantly reduced blood glucose from 539.2 ± 58.20 mg/dl to 463.9 ± 32.48 mg/dl, 
whereas metformin significantly reduced blood glucose from 467.2 ± 92.72 mg/dl to 272.8 ± 
67.56 mg/dl in a 3 hour period. 
 
Figure 17: Effect of glibenclamide (5 mg/kg BW) on blood glucose of FR10+STZ group 
over a 3 hour period at week 7 of the experimental period. Data are expressed as mean ± 




































Figure 18: Effect of metformin (500 mg/kg BW) on blood glucose (mg/dl) over a 3 hour 
period in FR10+STZ group at week 9 of the experimental period. Data are expressed as 
mean ± SD of 6 animals. *p < 0.05 vs. 0 minutes and #p < 0.05 vs. 120 minutes (Tukey-




































2.3.7 Serum lipid profile 
Table 2 shows the serum lipid profile of the different animal groups. FR10+STZ displayed 
significantly higher total cholesterol and serum triglyceride levels compared to the NC group, 
however, no significant differences for HDL or LDL cholesterol were observed between the 
groups.  
 
Table 2: Serum lipid profile of different animal groups at the end of the experimental 
period. 
Rat groups/ serum 
lipids 







Total cholesterol 69.40 ± 9.26 80.80 ± 13.48 90.50 ± 14.01* 
HDL cholesterol 18.60 ± 3.91 26.00 ± 8.09 24.83 ± 3.76 
LDL cholesterol 32.12 ± 11.01 33.40 ± 13.13 39.10 ± 12.43 
Triglycerides 93.40 ± 21.55 107.00 ± 17.38 132.83 ± 18.59* 
 
Data are shown as mean ± SD of 6 animals.*p < 0.05 vs. NC. (Tukey-Kramer multiple range 








2.3.8 Liver weights and liver glycogen 
Table 3 shows a non-significantly increased liver weight and relative liver weight % ([liver 
weight/body weight] x 100 %) in the FR10+STZ group compared to the control groups. 
Significant increases in liver glycogen were, however, noted in the diabetic (STZ and 
FR10+STZ) groups compared to the NC group. 
Table 3: Liver weights and liver glycogen levels in different animal groups at the end of 
the experimental period. 






Liver weight (g) 14.81 ± 2.65 13.71 ± 1.26 15.30 ± 0.99 
Relative liver weight (%) 3.13 ± 0.23 4.10 ± 0.08 4.22 ± 0.22 
Liver glycogen (mg/g tissue) 2.66 ± 1.23 22.05 ± 1.55* 23.81 ± 0.66* 
 
Data are shown as mean ± SD of 6 animals. 











2.3.9 Liver function enzymes and serum creatinine 
Table 4 shows the levels of liver function enzymes and serum creatinine in the serum of 
different animal groups. The highest AST concentration amongst the groups was observed in 
the FR10+STZ group; however the differences were not significant. The FR10+STZ group 
displayed a significantly higher concentration of ALT compared to the NC group, however, 
no significant differences were noted between the NC and STZ groups. Serum creatinine, on 
the other hand, can be used to assess insulin resistance indirectly. The STZ and FR10+STZ 
groups displayed significantly lower serum creatinine compared to the NC group at the end of 
the experimental period. 
 
Table 4: Serum AST, ALT and creatinine levels at the end of the experimental period. 










47.20 ± 3.03 
0.48 ± 0.06 
58.40 ± 12.10 
0.38 ± 0.07* 
66.83 ± 15.78* 
0.33 ± 0.05* 
 
Data are shown as mean ± SD of 6 animals. *p < 0.05 vs. NC (Tukey-Kramer multiple range 








2.3.10 Serum insulin and HOMA-IR and HOMA-beta scores 
Analysis of serum insulin concentration seen in Table 5 demonstrated a significantly lower 
serum insulin concentration in FR10+STZ compared to the control groups, however there 
was no significant difference between STZ and NC. HOMA-IR (insulin resistance) and 
HOMA-beta (pancreatic ß-cell function) are independent predictors of T2D. They are 
calculated based on fasting blood glucose and fasting serum insulin concentrations. From the 
calculation given below, Table 6 shows the HOMA-IR (insulin resistance) score was 
significantly higher in the FR10+STZ group compared to the controls and the HOMA-beta 
(pancreatic ß-cell function) score was significantly lower in the STZ and FR10+STZ groups 
compared to the NC group. 
HOMA-IR     = [Insulin (U/L) x Blood glucose (mmol/L)]/ 22.5 
HOMA-beta = [20 x Insulin (U/L)] / [Blood glucose (mmol/L) – 3.5] 
Conversion factor: Insulin (1U/L = 7.174pMol/L) and Blood glucose (1mmol/L = 18 mg/dl) 
Table 5: Serum insulin and calculated Homeostasis Model Assessment (HOMA) scores 
at the end of the experimental period. 









121.79 ± 43.70 
4.35 ± 1.12 
104.94 ± 40.83 
79.13 ± 22.38 
4.55 ± 2.69# 
40.78 ± 16.19# 
65.45 ± 20.77*# 
9.44 ± 2.35* 
29.37 ± 6.75* 
 
Data are shown as mean ± SD of 6 animals. The abbreviations denote HOMA-IR: 
Homeostasis model assessment of insulin resistance, HOMA-B: Homeostasis model 
assessment of pancreatic ß-cell function. *p < 0.05 vs. NC and #p < 0.05 vs. STZ (Tukey-





2.3.11 Histopathological examination of pancreatic tissue 
The slides for histopathological examination of pancreatic tissues are presented in Figures 19-
21. The slides revealed a reduced pancreatic ß-cell numbers in the STZ and FR10+STZ 
groups compared to the NC group. Severe damage of pancreatic islets was seen in the STZ 
group with deformed ß-cells. On the other hand, FR10+STZ group revealed a significantly 
smaller islet size, yet better physiological shape with a considerable number of healthy β-cells 
compared to STZ group. 
Figure 19a-d: Pancreatic islets containing β-cells in the NC group (a & b x1000; c & d 
x400). White arrows indicate pancreatic islets, with dark round spots inside (black arrows) 






Figure 20a-d: Pancreatic islets containing β-cells in the STZ group (a & b x1000; c & d 
x400). White arrows indicate pancreatic islets, with dark mass inside (black arrows) 






Figure 21a-d: Pancreatic islets containing β-cells in the FR10+STZ group (a & b x1000; 
c & d x400). White arrows indicate pancreatic islets, with dark round spots inside (black 








The primary objective of the study was to develop an alternative non-genetic rat model for 
T2D that may mimic the clinical pathogeneses seen in humans particularly insulin resistance 
and partial pancreatic β-cell dysfunction and which can be developed in an easier way and 
within a shorter period of time compared to several existing non-genetic animal models of 
T2D (Masiello et al., 1998, Reed et al., 2000, Srinivasan et al., 2005). Our results 
demonstrate that feeding a 10% fructose solution in combination with a 40 mg/kg BW STZ 
injection can be an easier and quicker way for the development of T2D in rats.                                                                 
According to the American Diabetes Association (ADA), the most common symptoms of 
diabetes include polydipsia and weight loss, which is sometimes accompanied by polyphagia   
and blurred vision (ADA, 2007). The polydipsia but not polyphagia was evidently present in 
the diabetic groups in our experiment. The significantly higher fluid intake but significantly 
lower BW gain in the FR10+STZ group compared to the control groups might be due to the 
severity of diabetic condition as well as higher energy expenditure via urinary glucose 
excretion in our experiment. In contrast to fat-fed-STZ-injected rat models, our model did not 
show a higher mean BW gain compared to NC rats. The fat-fed-STZ-injected rat model 
attributed the higher weight gain due to the intake of high fat diet which being deposited as 
fat pads around the body (Srinivasan et al., 2005). In our experiment, the FR10+STZ group 
did not exhibit actual weight loss as seen in T1D patients and animal models (Hessner et al., 
2004) but rather decreased weight gain as compared to the control groups.   
The ADA also reported that the FBG >100 mg/dl but <126 mg/dl, blood glucose at 2 hours 
post-glucose load >140 mg/dl but <200 mg/dl and fasting plasma glucose (FPG) >140 mg/dl 
and/or 2 hours post-glucose load >200 mg/dl are respectively considered as impaired fasting 
glucose (IFG), impaired glucose tolerance (IGT) and diabetes (ADA, 2007). On the other 
hand, recently it has been reported that FBG cannot be always considered as an authentic 
marker for the diagnosis of T2D (Islam, 2011). In our experiment, FBG levels in the first two 
weeks and even one week after the STZ injection were not significantly different between the 
groups and they were at normal glucose level (<100 mg/dl mean). Hence, NFBG was 
measured during the remaining period of the experiment. The NFBG of STZ and FR10+STZ 
groups were significantly higher than the NC group (Fig. 3). However, the NFBG range of 
FR10+STZ group was significantly higher than the STZ group (300-450 vs. 200-250 mg/dl). 
Like many other studies (Can et al., 2011, Islam and Choi, 2008, Srinivasan et al., 2005) the 
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NFBG >300 mg/dl has been used as a cut-off point for T2D which has been maintained by 
FR10+STZ but not by STZ group in our experiment. Additionally, our model demonstrated 
sensitivity to both metformin (glucophage) and glibenclamide by significantly reducing blood 
glucose levels over a 3 hour period.   
Not always but in many cases hyperinsulinemia, besides hyperglycemia, has been reported as 
a consequence of T2D. As the disease state progresses to chronic hyperglycemia in Type 2 
diabetics, insulin secretions become impaired and decline (Nattrass and Bailey, 1999). It has 
been reported that dietary fructose stimulates less insulin secretion but increased food intake 
compared to glucose and glucose-containing carbohydrates in humans (Bantle and Slama, 
2006). Our results demonstrated a significantly (p < 0.05) lower serum insulin concentration 
in FR10+STZ rats as compared to NC rats (Table 5). FR10+STZ rats also displayed a lower 
serum insulin concentration than STZ rats indicating that fructose may play a role in the 
reduction of circulating insulin possibly due to its very high glycation potentials (Obrosova, 
2005) that could lead to the formation of advance glycation end products with concomitant 
generation of oxidative stress. This oxidative stress has been reported as a major contributor 
to the β-cell damage in T2D (Obrosova, 2005), thus, partial pancreatic ß-cell dysfunctioning 
might not be solely attributed to STZ. Based on our histopathological findings, however, we 
speculate that the combined effect of STZ and fructose in fact minimizes the oxidative 
damage on pancreatic β-cells than the oxidative stress that would be produced by the 
individual agents alone.  
In addition to serum insulin concentrations, HOMA-beta scores are often used to validate 
pancreatic β-cell function (Matthews et al., 1985, Song et al., 2007). Our results show a 
dramatic decrease (p < 0.05) in HOMA-beta scores in FR10+STZ groups as compared to NC 
rats. Although the use of STZ amongst researchers is very common for the induction of 
diabetes or hyperglycemia (Etuk, 2010, Koulmanda et al., 2003), higher doses of STZ 
induced models resembling T1D. Hence the development of insulin resistance along with 
pancreatic β-cell dysfunction by using a single diabetic inducer may not be possible. Several 
attempts have been made to combat this shortcoming to induce typical pathogenesis of T2D, 
through the use of high-fat diet-fed STZ-injection (Reed et al., 2000, Srinivasan et al., 2005), 
multiple low-dose STZ injections (Zhang et al., 2008) and a combination of nicotinamide and 
STZ injection (Masiello et al., 1998, Nakamura et al., 2006) in several previous studies. 




In order to understand the level of pancreatic damage in our model, histopathological 
examinations of pancreatic islets were performed. Although the pancreatic weights were not 
significantly reduced (data not shown), the pancreatic islet size in FR10+STZ group were 
significantly reduced compared to the STZ and NC groups (Fig. 7) paralleling the HOMA-
beta scores, which further accounts for significant reductions in circulating serum insulin and 
insulin production. The healthier morphological appearance of pancreatic ß-cells in the 
FR10+STZ group than in the STZ group also confirms the stability of animals for a longer 
period of time. In fact, the STZ pancreatic islets revealed substantial damage, which was not 
noted in the FR10+STZ group. We speculate that fructose may compromise the effect of STZ 
by an unknown mechanism, resulting in the morphologically better appearance of the islets in 
the FR10+STZ group compared to the STZ group. 
Recently, creatinine has been found to be a new risk factor for T2D and insulin resistance 
(Harita et al., 2009). Creatinine is a metabolite derived from creatine, which is predominantly 
(>98%) found in skeletal muscle, the major site for insulin action and subsequent glucose 
disposal. Harita et al. (2009) proposed that if muscle mass is inversely proportional to insulin 
resistance but directly proportional to serum creatinine then serum creatinine could provide a 
conclusive measure to assess insulin resistance. Their study showed that lower serum 
creatinine level is a risk factor for the development of T2D in lean, non-obese Japanese 
males. More recently, Hjelmesæth et al. (2010) validated this finding as their research 
showed that the lower serum creatinine level can predict T2D in morbidly obese Caucasian 
patients. Our data showed a significantly lower (p < 0.05) serum creatinine level in diabetic 
rats as compared to NC rats coupled with significant increases in HOMA-IR in FR10+STZ 
rats emphasizing a state of insulin resistance in this group.   
Hyperlipidemia is another factor directly linked to insulin resistance as high circulating lipid 
concentrations in the blood secrete humoral factors such as resistin and adiponectin that alter 
insulin sensitivity, leading to insulin resistance (Barnes and Miner, 2009, Trujillo and 
Scherer, 2006). Diets high in fructose cause hyperlipidemia and hypertension in various 
animal models (Hwang et al., 1987) and have been linked over the years to insulin resistance 
(Tappy and Lȇ, 2010). This is partly because fructose metabolism cannot be controlled by 
insulin or leptin, which are important factors for the regulation of fat synthesis as well as 
energy intake (Basciano et al., 2005). Additionally, fructose has been shown to be more 
hyperlipidemic than both glucose and starch with increased levels of LDL, VLDL and total 
cholesterol in rats (Benado et al., 2004). Several recent studies have been reported that higher 
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serum triglycerides alone or accompanied with low serum HDL-cholesterol is a risk factor for 
hepatic insulin resistance as well as T2D (Elliot et al., 2002, Singla et al., 2009). The 
significantly higher serum total cholesterol and triglyceride levels in the FR10+STZ group, 
but not in STZ group, compared to the NC group could be the reasons for higher insulin 
resistance in the FR10+STZ group compared to other groups.  
In addition, higher level of liver-function enzyme e.g. alanine transaminase (ALT) and 
aspartate transaminase (AST) in serum are not only  used for the identification of liver 
damage (Harris, 2005) but also for the hepatic insulin resistance, metabolic syndrome as well 
as T2D (Cho et al., 2007). In a recent study, Cho et al. (2007) found a strong correlation 
between serum ALT level and  HOMA-IR scores but not for the AST, and it has been 
indicated as a predictor of T2D in human subjects. The significantly (p < 0.05) higher level of 
serum ALT level in FR10+STZ group compared to NC group also suggest the higher level  
of insulin resistance in this group. Furthermore, as ALT is not commonly elevated in T1D, it 
can be a strong and independent predictor for T2D, (Harris, 2005) which is reflected in our 
model. 
In conclusion, this study shows that the 10%-Fructose-fed-40 mg/kg BW-STZ-injected rat 
can be a new and alternative model for T2D due to its quick induction time that successfully 
induces both pathogeneses of T2D, insulin resistance and partial pancreatic ß-cell 
dysfunction. The model demonstrated a stable diabetic condition over an 11 weeks 
experimental period and can be used for both acute and chronic research studies as well as 
being useful for routine pharmacological screening of anti-type 2 diabetic materials. It is easy 
to develop, highly cost-effective and can be used by researchers world-wide, especially in 
developing countries, where funding and resources are limited. As neither special formulation 
of diets nor sophisticated instruments is required, this model can be developed in an animal 





CHAPTER 3 Intervention Trial 
3.1 Intervention trial background 
One of the major aims of current research is to improve existing models or develop novel 
models that may better reflect the pathogenesis of type 2 diabetes (T2D). These models 
require to be validated through pharmacological screening of routine anti-diabetic drugs. The 
initial findings in chapter 3 revealed that the 10%-fructose-fed-STZ-injected rat was highly 
responsive to T2D drugs. To validate the initial findings, a more comprehensive intervention 
trial study was required by testing not only commonly employed anti-diabetic agents but also 
through the use of natural products believed to have anti-diabetic properties. 
Despite the wide availability and range of existing anti-diabetic drug therapies, there is still 
an ever-growing need for better and/or alternative therapies to combat the rising numbers of 
global diabetic patients. Furthermore, the need for new therapies is increasing due to their 
cheaper cost, wider availability and to avoid the dissatisfactory symptoms and consequences 
of traditional drug therapies, including weight gain and hypoglycaemia or certain 
contraindications that may limit their use (Amin and Nagy, 2009; Tahrani et al., 2010). 
Because T2D is characterised by 2 pathogeneses, insulin resistance and partial pancreatic β-
cell dysfunction (Stumvoll et al., 2005), these are two targets for disease control. Insulin 
resistance precedes the development of T2D by many years (Faccini et al., 2001) with obesity 
being labelled the “single most important contributor” to insulin resistance (Kahn et al., 
2006; Tahrani et al., 2010). The global prevalence of overweight and obesity are rapidly 
increasing not only in adults but also in young adolescents and children (Canbakan et al., 
2008). Obesity has not only been associated with insulin resistance but also with the 
development of T2D and other complications such as cardiovascular disease and coronary 
heart disease (Lavie et al., 2008). At the same time, the reasons for the progression toward 
pancreatic β-cell dysfunction largely involve hyperglycemia and hyperinsulinemia. 
Achieving glycaemic control in those already suffering with T2D and preventing further 
pancreatic damage are thus other important therapeutic targets. For this reason, in the 
following experiment, an agent known as L-carnitine (CARN) with potential to reduce 
obesity, weight gain, cholesterol, and potential for anti-diabetic effects, as well as white 








Figure 22: Chemical structure of L-Carnitine (www.bmrb.wisc.edu) 
L-carnitine (ß-hydroxy-γ-N-trimethylammonium-butyrate) is ingested in the human diet from 
meat and dairy products, which accounts for 75% of adult carnitine requirements (Stanley, 
2004). Besides the diet, carnitine can also be endogenously synthesized in the liver, kidneys 
and brain from two essential amino acids, methionine and lysine (Flanagan et al, 2010, 
Scaglia and Longo, 1999). L-carnitine is a compound that is vital for fat metabolism in the 
body as it facilitates ATP energy through the oxidation of fatty acids (Gómez-Amores et al., 
2007). L-Carnitine plays an essential role in β-oxidation, not only through the generation of 
ATP, but also through transportation of long-chain fatty acids from the cytosol into the 
mitochondrion (Amat di San et al., 2008). Deficiencies in L-carnitine are therefore linked to 
the body’s inability to utilise lipids as a source of fuel (Seccombe et al., 1987, Amat di San et 










Figure 23: Transportation shuttling of long-chain fatty acids into the mitochondria for 
β-oxidation (Copied without permission from Flanagan et al., 2010). FATP = Fatty acid 
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transport protein  , CPT I = carnitine palmitoyltransferase 1, CPT II = carnitine 
palmitoyltransferase II, CACT = carnitine acylcarnitine translocase 
Furthermore it is a potent antioxidant in the body as it is a scavenger of free radicals and 
protects cells from endogenous reactive oxygen species (ROS). ROS is a leading cause of 
oxidative stress, which results in partial pancreatic ß-cell dysfunction as well as hypertension 
and various other complications of the diabetic condition (Jingbo et al., 2010). In addition, L-
carnitine has been shown to reduce lipid peroxidation when orally administered (Clark et al., 
2007). Several studies have indicated its benefits in atherosclerotic rats and 
hypercholesterolaemic rabbits (Gómez-Amores et al., 2007). Furthermore, reports have 
indicated that L-carnitine reduces oxidation of LDL cholesterol. This finds benefit in diabetic 
patients due to the high level of oxidative stress found in these subjects (Motta et al., 2006, 
Motta et al., 2008). Oxidation of LDL cholesterol enhances the formation of “cholesterol-
laden foam cells” (Malaguarnera et al., 2009), which form a significant component in 
atherosclerotic plaques (Steinberg, 1997, Boullier et al., 2001). These are both important 
disease complications of T2D and hence indicate its potential use as an anti-diabetic agent. L-
carnitine deficient rats administered with L-carnitine resulted in the normalization of blood 
pressure, (Kraemer et al., 2008) which is a necessary factor in diabetic patients suffering with 
elevated blood pressure and hypertension. 
The liver is the primary site of L-carnitine metabolism, hence it may have a therapeutic 
benefit in diseased liver conditions. In fact, Yapar et al. (2007) found that L-carnitine 
administration significantly lowered the activity of functional liver enzymes AST and ALT in 
obese rats. Other studies revealed L-carnitine administration resulted in a reduction in insulin 
resistance in T2D patients when assessed using the euglycemic hyperinsulinemic clamp 
method (Capaldo et al., 1991). 
Low HDL and high serum triglyceride levels have been deemed a risk factor for the 
development of T2D (Singla et al., 2009). In 2004, studies conducted by Eskandari and co-
workers found that diabetic rats induced by streptozotocin followed by L-carnitine treatment 
at a dose of 100 mg/kg body weight (BW) per day for 10 days showed both lower total 
cholesterol and triglyceride levels. They concluded that L-carnitine has hypotriglyceridemic 
and hypocholesterolemic potential and further studies must be done to evaluate its 
effectiveness as a potential agent for treatment of T2D. Importantly there is evidence that L-
carnitine serves to enhance the glycolytic pathway – the major pathway of carbohydrate 
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metabolism. This is achieved as it enhances the activity of pyruvate dehydrogenase resulting 
in the reduction of acetyl CoA, which subsequently activates the glycolytic pathway 
(Mingrone et al,.1999). It can be suggested that through this mechanism L-carnitine can 
improve glucose disposal and hence lower hyperglycaemia/blood glucose. It is therefore of 
extreme importance and relevance to investigate L-carnitine as a therapeutic agent against 
T2D and determine all effects on parameters of T2D, including liver enzymes, kidney 
function, lipid profiling, body weight, food and fluid intake as well as serum proteins and uric 
acid levels. 
On the other hand, white mulberry (Morus alba) has been used over the centuries in 
Traditional Chinese Medicine as a common agent to treat a variety of conditions including 
atherosclerosis, diabetes, cancer as well as for boosting the immune system and offering 









Figure 24: Classification and identification of White Mulberry (Morus alba) (Copied 
without permission from Butt et al., 2008) 
With regards to diabetes, the root and bark are often used to reduce hyperglycemia (high 
blood sugar) (Bantle and Slama, 2006). Different parts of the Mulberry plant (fruit, bark, leaf 
and root) have drawn interest in their role to treat diabetes as a result of the different chemical 
components found in the various plant constituents. One such component, 1-
deoxynojirimycin (DNJ), found in both the leaves and the bark, is a polyhydroxylated 
piperidine alkaloid known to be a potent α-glycosidase inhibitor (Oku et al., 2006) which aids 
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to slow down the uptake of carbohydrates and hence help manage blood glucose levels. 
Kimura and coworkers (2007) found that a single dose of DNJ in humans of 0.8 and 1.2g 
significantly lowered non-fasting blood glucose levels and insulin secretion. Whilst the anti-
diabetic effects of the root and bark has been known for centuries, only recently, the leaves 
used in the brewing of tea has gained a great deal of interest as a potential anti-diabetic drink 
(Butt et al., 2008). Studies conducted by Hansawasdi and Kawabata (2006) showed that 1.0% 
mulberry tea solution had inhibitory effects against sucrose, maltase and α-glucosidases, 
preventing the digestion of carbohydrates and delaying their absorption, ultimately reducing 
blood glucose levels. White mulberry contains a significant concentration of anti-oxidative 
compounds. Mulberry leaves are found to contain phenolic compounds, flavonoids. Mulberry 
leaves prevent lipid peroxidation in diabetic patients by reducing catalase activity and 
increasing glutathione concentrations (Andallu and Varadacjaryulu, 2003). Mulberry leaf 
extracts inhibit oxidation of LDL cholesterol and thus find benefit in treating atherosclerosis 
(Enkhmaa et al., 2005). In LDL deficient mice, consumption of mulberry leaves lowered 
LDL oxidation, resulting in a reduction of atherosclerotic lesion areas (Katsube et al., 2006). 
The tea has not yet been tested in animal models and is highly relevant to determine its anti-
diabetic effects. Furthermore, due to its potent antioxidant activity, it may serve to offer 
protection against later diabetic complications (such as neuropathy and cardiomyopathy) and 
requires investigation on other diabetic parameters. 
3.2 Materials and method 
3.2.1 Reagents and materials 
STZ (>98%) (Sigma-Aldrich) was purchased from Capital Lab Supplies cc. Durban, South 
Africa.  Glucostrips, and Fructose (Nature’s Choice™ Wholefood specialists, Meyerton, 
South Africa 1960) were purchased from a local pharmacy. L-carnitine was purchased from 
Sunrise Chemical co. (South Africa). White mulberry tea was purchased from Beautique Thai 
(Thailand). A glucometer (GlucoPlus Inc, Quebec, Canada, measuring up to 600 mg/dl) was used 
for measuring fasting and non-fasting blood sugar levels. Serum analysis was conducted 







Thirty five (6 weeks of age) male Sprague-Dawley rats (mean similar weight 191.88g ± 
16.40g) were procured from the Biomedical Resource Unit (BRU) at Westville Campus from 
the University of KwaZulu-Natal, South Africa. Animals were randomly subdivided into 5 
groups of 7 rats in each group as follows: Normal Control (NC), Diabetic/Streptozotocin 
control (FR10+STZ), Mulberry Tea Low (0.25%) (FR10+STZ+MTL), Mulberry Tea High 
(0.5%) (FR10+STZ+MTH) and L-Carnitine (FR10+STZ+CARN). Two rats per poly-
carbonated cage were housed in a temperature and humidity controlled room with a set 12 
hour light-dark cycle. The rats were fed a commercially available rat chow diet ad libitum 
throughout the entire 9 week experimental period. The NC group was supplied with normal 
drinking water ad libitum whilst all other groups were supplied with a 10% fructose solution 
in drinking water for 2 weeks only to induce insulin resistance. Hereafter all groups except 
the MT groups were supplied with normal drinking water for the remainder of the 
experiment. The animals were maintained according to the rules and regulations of the 
University of KwaZulu-Natal (UKZN) Animal Ethics Committee (Ethical approval number: 
029/11/Animal).  
3.2.3 Induction of diabetes 
STZ was dissolved in a citrate buffer (pH 4.4). The solution was then filtered through a 
sterilized 0.45 millipore filter. Each of the fructose-fed groups were injected intraperitoneally 
in the fasted state with a low dose STZ injection (40 mg/kg BW) whilst the normal control 
group (NC) received a vehicle citrate buffer (pH 4.4) injection only. 
Non-fasting blood glucose (NFBG) levels of all animals was measured 1 week after STZ 
injection. Blood was taken from the rat tail veins using a 25G needle and FBG was measured 
using a portable glucometer (GlucoPlus Inc, Quebec, Canada). Animals with a non-fasting 
blood glucose (NFBG) level > 300 mg/dl were considered diabetic. NFBG levels were 
measured (Week 1-9) weekly. The rats were firstly fasted for a 12 hour period, after which 
food was returned ad libitum for 3 hours and then subsequent NFBG was measured. During 
the fasted period, all groups received normal drinking water and the amount consumed after 
the 12 hour period was recorded. During the 3 hour feeding period prior to NFBG 
measurements, intervention materials were administered returned, whilst the control groups 
continued to consume normal drinking water throughout this period. 
62 
 
3.2.3.1 Food and fluid intake, body weight and intervention materials 
 Daily food and fluid intake were monitored and weekly body weight changes were measured 
during the entire experimental period. Mulberry tea was prepared in the following 
concentrations: 0.25% and 0.5%. The tea was brewed for 10 minutes and cooled to room 
temperature. Mulberry tea was supplied ad libitum during week 4-8 of the intervention trial. 
L-Carnitine was prepared by dissolving in distilled water at a concentration of 250 mg/ml. L-
carnitine was administered to the CARN group at a concentration of 500 mg/kg BW once 
daily in the morning during week 4-8 of the intervention trial. 
3.2.4 Oral glucose tolerance test 
After an overnight fast (12 hours), rats were orally dosed with a D-glucose solution (2.0 g/kg 
BW) at week 8 of the experimental period. Glucose concentrations were subsequently 
measured by blood collection from the tail veins at 0 (just prior to oral glucose dosing), 30, 
60, 90 and 120 minutes after oral dosing and blood glucose levels monitored with a 
glucometer.  
3.2.5 Collection of blood, liver, pancreas, kidneys, heart and brain 
At the end of the experimental period animals were fasted for 14 hours prior to euthanasia by 
halothane anaesthesia. Animals were weighed before euthanasia after which blood, liver, 
heart, kidneys and pancreas were collected. Blood was collected through cardiac puncture 
using a 21G needle and fasting blood glucose levels were immediately measured using a 
portable glucometer. Blood samples were subsequently placed in heparin tubes and allowed 
to coagulate on ice for approximately 3 hours and then centrifuged at 3000 rpm for 15 
minutes. Hereafter, serum was separated into labeled microtubes and stored at -30˚C for 
further analysis. Liver, kidney, brain and heart samples were washed in cold 0.9% saline 
solution, wiped dry with filter paper, weighed on an analytical balance and preserved at -30˚C 
for further analysis. The hypothalamus was frozen in liquid nitrogen and stored for further 
analysis. Part of the pancreas sample was immediately fixed in 10% neutral buffered formalin 
solution for histopathological examinations, which was replaced weekly during the entire 





3.2.6 Analytical methods 
Liver glycogen concentration was measured photometrically by using the Phenol-Sulphuric acid 
method as described by Lo et al. (1970). Serum insulin was analyzed using an ultra sensitive rat 
insulin ELISA kit (Mercodia AB, Uppsala, Sweden) using a multi plate ELISA reader 
(Biorad-680, BIORAD Ltd., Japan).  
Serum lipid profiles, serum creatinine and liver function enzymes (AST and ALT) were 
measured using an automated chemistry analyzer (Labmax Plenno, Labtest, Brazil). Total 
cholesterol was measured directly in the serum according to the following principle: 
Cholesterol + O2  
cholesterol oxidase> Cholest-4-en-one + H2O2. 
H2O2+ phenol + 4-aminoantipyrine  
peroxidase> Quinonemine + 4H2O. 
Quinonemine is maximally absorbed at 500 nm. The intense red colour generated is directly 
proportional to the cholesterol concentration in the sample. LDL cholesterol was 
quantitatively precipitated after centrifugation. Triglycerides are measured in a similar 
manner to total cholesterol to yield quinonemine. The red colour that is produced is directly 
proportional to triglyceride concentration.  
Creatinine was measured according to the following test principle: 
Creatinine + alkaline picrate −−−→ Creatinine picrate  
This yields an intense red colour. This red colour is directly proportional to the concentration 
of creatinine at 510 nm.  
Liver enzyme ALT was measured according to the following test principle:  
L-Alanine + ketoglutarate 
ALT
>  Pyruvate + L-glutamate 
Pyruvate + NADH 
LDH
>  Lactate + NAD 
NADH oxidation at 340 nm is directly proportional to the ALT activity in a sample. AST is 
measured in an almost identical manner: 
L-Aspartate + ketoglutarate 
AST
>  Oxaloacetate + L-glutamate 
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Oxaloacetate + NADH 
LDH
>  Lactate+ NAD 
Fructosamine is formed when glucose binds to amino acids in the blood and rearranges 
molecularly to form fructosamine. In an alkaline pH, fructosamine reduces blue tetrazolium 
to purple formazan which can be directly measured at 530 nm.  
Uric acid can be measured in serum in the following 2 step reaction: 
Uric acid+ 2H2O+ O2  uricase> Allantoin + CO2 + H2O2. 
2H2O2 + DHBS +4-aminoantipyrine  
peroxidase> Quinonemine + 4H2O. 
Quinonemine yields an intense red quinonemine measured between 490-540 nm. This is 
directly proportional to the concentration of serum uric acid in a sample.  
Total proteins and serum albumin are measured by the principle that in alkaline conditions, 
copper ions react with peptide bonds in proteins to yield a purple colour that is maximally 
absorbed at 545 nm and is directly proportional to the concentration of proteins and albumin 
in a serum sample.  
3.2.7 Liver glycogen content 
Liver glycogen content was measured photometrically according to the Phenol-Sulphuric acid 
Method developed by Lo et al. (1970). Liver samples of ≤ 1.0g were measured and placed at 
the bottom of a screw-capped pyrex tube using forceps and then placed on ice. The sample 
was then immersed in 1.5ml of 30% KOH saturated with Na2SO4. This was then placed in a 
boiling water bath for 20-30 minutes. The sample was then removed and allowed to cool on 
ice. 2ml of 95% ethanol was then added and placed on ice for a minimum of 30 minutes. 
Samples were centrifuged at 840 x g (2812 rpm) for 25-30 minutes. The supernatant was 
aspirated and the glycogen precipitate was dissolved in 3.0ml distilled water. 50µl of this 
solution was transferred to a clean test tube containing 450µl distilled water. This was 
performed in duplicate. Glycogen standards were prepared from a stock solution of 1 mg/ml 
glycogen (Oyster, Type II, SIMGA-ALDRICH, USA) at concentrations of 10, 20, 40, 80, 
160, 320 and 640µg/ml. To both the standards and samples, 0.5ml of 5% phenol was added to 
each test tube, followed by the rapid addition of 2.5ml 96-98% H2 SO4. This was left to stand 
at room temperature for 10 minutes, after which the absorbance was read in a photometer at 
490nm. A solution of distilled water served as the blank. The concentration of liver glycogen 
65 
 
was thereafter calculated from a liver glycogen standard curve. This experiment was 
performed in triplicate. 
3.2.8 Serum insulin analysis 
Rat serum analysis was performed using a Ultrasensitive Rat Insulin ELISA kit from 
Mercodia (Uppsala, Sweden). This kit was supplied with a method for the quantitative 
determination of serum insulin. It makes use of a direct technique whereby 2 monoclonal 
antibodies act against different antigenic sites on the insulin molecule. Insulin contained in 
the rat serum reacts with a peroxidase-conjugated anti-insulin antibody during incubation. 
The several washing steps removed any unbound enzyme-labelled antibodies. The bound 
conjugate is then detected through the reaction with 3,3’,5,5’-tetramethylbenzidine. This 
reaction is then stopped by the addition of acid giving rise to a yellow colour that is read 
photometrically at 450nm. This experiment was performed through the development of a 
serum insulin standard curve using 50µl of a range of calibrators from Calibrator 0-7. In 
separate wells, 50µl of serum sample was added after which 50µl of enzyme conjugate was 
added to all wells. This was incubated on a shaker at 700-900rpm for 2 hours at room 
temperature. Hereafter, the solution was aspirated followed by 6 wash steps of 350µl of 21x 
wash buffer. At the last wash step, the plate was inverted and tapped firmly against absorbent 
paper towel. 200µl of Substrate TMB was added to all wells. This was incubated for 30 
minutes to develop a blue colour. After 30 minutes, a stop solution comprised of acid was 
added to all wells in 50µl aliquots. This was shaken for 5 seconds to ensure adequate mixing 
of Substrate TMB and the stop solution. The absorbance was read in triplicate using a 
multiplate reader ((Biorad-680, BIORAD Ltd., Japan) at 450nm. 
3.2.9 Statistical analysis 
All data are presented as mean ± SD. The data were analyzed by a statistical software 
package (SPSS version 18) using the Tukey-Kramer multiple range post-hoc test. The values 






3.3.1 Food intake during intervention trial 
Figure 25 represents the mean food intake (g) per animal per day during the intervention trial 
period. The NC group displayed significantly lower food intake compared to all groups, 
whilst the FR10+STZ+MTL group displayed significantly higher food intake compared to all 
other groups. There were no statistical differences of the food intake between the FR10+STZ 
(50.72 ± 4.62g), FR10+STZ+MTH (50.81 ± 5.76g) and FR10+STZ+CARN (49.38 ± 8.08g) 
groups.  
 
Figure 25: Mean food intake (g) per animal per day during the intervention period. *p < 

















































3.3.2 Mean fluid intake during intervention trial 
Figure 26 shows the mean fluid intake (ml) per animal per day during the invention trial 
period. The graph shows the NC group displayed a significantly lower fluid intake compared 
to all other groups, whilst the FR10+STZ+MTL (198.24 ± 17.46ml) group displayed 
significantly higher fluid intake compared to all groups. No statistical differences were noted 
between FR10+STZ (179.84 ± 27.99ml) and FR10+STZ+MTH (175.37 ± 21.11ml), 
however, FR10+STZ+CARN (163.83 ± 26.08ml) displayed significantly lower fluid intake 
compared to the FR10+STZ group.  
 
Figure 26: Mean fluid (ml) intake per animal per day during the intervention trial 
period. *p < 0.05 vs. NC, #p < 0.05 vs. FR10+STZ, †p < 0.05 vs. FR10+STZ+MTL. (Tukey-















































3.3.3 Mean body weight over the experimental period 
Figure 27 represents the mean body weight over the 9 week experimental period. The first 3 
weeks reveal no significant changes in body weight until the induction of diabetes through 
the intraperitoneal injection of streptozotocin. One week after the streptozotocin injection and 
all experimental groups displayed significant reduction in body weight compared to the NC 
group. This weight loss is a common symptom of streptozotocin and is quickly recovered. 
Throughout the intervention period, all experimental groups including FR10+STZ displayed 
significantly reduced body weight compared to the NC group, however there were no 
statistical differences among the groups. FR10+STZ+MTH and FR10+STZ+CARN 
displayed non-significantly reduced body weight compared to FR10+STZ, with 
FR10+STZ+MTL having a non-significantly increased body weight compared to FR10+STZ. 
FR10+STZ+CARN displayed the lowest body weight over the experimental period.  
 
Figure 27: Mean body weight (g) over the 9 week experimental period.*p < 0.05 vs. NC. 






















































3.3.3.2 Mean body weight gain 
Figure 28 depicts the mean body weight gain over the entire 9 week experimental period. The 
NC group displayed significantly higher body weight gain compared to all groups. The 
experimental groups showed no significant differences compared to the FR10+STZ (24.8 ± 
18.79g) group, however both MT groups were non-significantly higher, whilst 
FR10+STZ+CARN (10.00 ± 15.49g) was non-significantly lower than FR10+STZ. 
FR10+STZ+CARN displayed the lowest overall weight gain and FR10+STZ+MTL (34.5 ± 
21.60g) displayed the highest overall weight gain of the diabetic groups.  
 
Figure 28: Mean weight gain over the experimental period. *p < 0.05 vs. NC. (Tukey-













































3.3.4 Non-fasting blood glucose  
3.3.4.1 Non-fasting blood glucose (mg/dl) of FR10+STZ+MTL during intervention trial. 
Figure 29 displays the NFBG of NC, FR10+STZ and FR10+STZ+MTL during the 
intervention trial period. FR10+STZ and FR10+STZ+MTL displayed significantly higher 
NFBG compared to NC. The NC group displayed extremely stable NFBG over the 4 week 
period with a mean NFBG ranging between 106 mg/dl to 109 mg/dl. The FR10+STZ group 
was not significantly different from FR10+STZ+MTL group over the experimental period 
with NFBG ranging between 562.60 - 599.40 mg/dl and 563.67-600.00 mg/dl respectively.   
 
 
Figure 29: Non-fasting blood glucose (mg/dl) of FR10+STZ+MTL group over 




































3.3.4.2 Non-fasting blood glucose (mg/dl) of FR10+STZ+MTH during intervention trial 
Figure 30 displays the NFBG (mg/dl) of the FR10+STZ+MTH group during the 4 week 
intervention trial. FR10+STZ and FR10+STZ+MTH displayed significantly higher NFBG 
compared to NC. The NC group displayed a mean NFBG ranging between 106 mg/dl to 109 
mg/dl. The FR10+STZ group was not significantly different from FR10+STZ+MTH group 
over the experimental period with NFBG ranging between 562.60 - 599.40 mg/dl and 572.80 
– 592.00 mg/dl respectively.   
 
Figure 30: Non-fasting blood glucose (mg/dl) of FR10+STZ+MTH during the 






































3.3.4.3 Non-fasting blood glucose (mg/dl) of FR10+STZ+CARN during intervention 
trial. 
Figure 31 displays the NFBG (mg/dl) of the FR10+STZ+CARN group during the 4 week 
intervention trial. FR10+STZ and FR10+STZ+CARN displayed significantly higher NFBG 
compared to NC. The NC group displayed a mean NFBG ranging between 106 mg/dl to 109 
mg/dl. The FR10+STZ group was not significantly different from the FR10+STZ+CARN 
group over the experimental period with NFBG ranging between 562.60 - 599.40 mg/dl and 
552.30 - 477.50 mg/dl respectively. Important to note is that no other experimental group 
except FR10+STZ+CARN displayed a trend pattern in the weekly NFBG measurements. 
FR10+STZ+CARN was the only group to display a consistent reduction each week in NFBG. 
Larger standard deviations can be noted on the FR10+STZ+CARN group compared to all 
other groups as one animal in this group displayed significant reductions from 421 mg/dl in 
week 1 to 179 mg/dl in week 4. 
 
 
Figure 31: Non-fasting blood glucose (mg/dl) of FR10+STZ+CARN during the 
intervention trial period. *p < 0.05 vs. NC. (Tukey-Kramer multiple range post-hoc test).  































3.3.5 Oral glucose tolerance test 
Figure 32 represents the OGTT during week 8 of the experimental period. Just prior to dosing 
2g/kg BW D-glucose (time 0 minutes), all groups except FR10+STZ+CARN had 
significantly higher FBG compared to NC. At time 0 minutes, FR10+STZ+CARN displayed 
significantly lower FBG than the FR10+STZ+MTL group. All groups peaked at 30 minutes 
after oral dosing. All groups were significantly higher than the NC group between 30-120 
minutes, and FR10+STZ+CARN also displayed significantly lower BG after 120 minutes 
compared to the FR10+STZ+MTL group. None of the experimental groups demonstrated a 
BG less than 200 mg/dl after 2 hours, indicating that the diabetic condition had not been 
reversed. The NC group ranged from 87.90 - 129.70 mg/dl, FR10+STZ from 301.20 -397.00 
mg/dl, FR10+STZ+MTL from 439.70 - 457.80 mg/dl, FR10+STZ+MTH from 305.80 - 
468.20 mg/dl and FR10+STZ+CARN from 231.80 – 387.00 mg/dl.  
 
Figure 32: Oral glucose tolerance test over a 2 hour period. *p < 0.05 vs. NC., †p < 0.05 
vs. FR10+STZ+MTL. (Tukey-Kramer multiple range post-hoc test).  
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3.3.6 Liver weight, relative liver % and liver glycogen 
Table 6 shows the liver weight, relative liver weight (%) and liver glycogen (mg/g liver 
tissue). No significant differences were noted among groups for liver weight, except for the 
FR10+STZ+CARN group, which displayed a significantly lower liver weight compared to 
the NC group. All groups, however, displayed a significantly higher relative liver weight and 
liver glycogen compared to the NC group, yet there were no statistical differences amongst 
the experimental groups themselves. 
Table 6: Liver weights and liver glycogen levels in different animal groups at the end of 
the experimental period. 
 
Data are shown as mean ± SD of 7 animals. *p < 0.05 vs. NC. (Tukey-Kramer multiple range 




































4.66 ± 3.61 11.97 ± 0.16* 11.46±1.25* 10.88 ± 2.67* 11.50 ± 0.63* 
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3.3.7 Serum insulin 
Figure 33 shows the serum insulin (pmol/L) concentration in different rat groups at the end of 
the experimental period. All diabetic groups displayed significantly lower serum insulin 
compared to the NC group, yet the experimental groups demonstrated a minor, albeit, non-
significant increase in serum insulin compared to the FR10+STZ group. FR10+STZ+CARN 
demonstrated the highest, although non-significant, concentration of serum insulin in the 
experimental groups, with FR10+STZ+MTH showing a higher serum insulin compared to 
FR10+STZ+MTL. 
 
Figure 33: Serum insulin (pmol/L) of the experimental groups after the experimental 















































3.3.8 Serum lipid profile 
Table 7 represents the serum lipid profile after the experimental period. FR10+STZ+MTH 
and FR10+STZ+CARN displayed significantly lower total cholesterol compared to 
FR10+STZ and FR10+STZ+MTL, yet none were statistically different from the NC group. 
FR10+STZ+MTL displayed significantly higher HDL cholesterol compared to FR10+STZ, 
but no other statistical differences were noted for this test. No statistical differences in LDL 
cholesterol were noted amongst the groups, however, FR10+STZ and FR10+STZ+MTL 
displayed significantly higher triglycerides compared to the NC group, whereas 
FR10+STZ+MTH and FR10+STZ+CARN were not statistically different from NC. 
FR10+STZ+CARN was significantly lower than the FR10+STZ group. 




















                          mg/dl   
Total 
cholesterol 
75.14 ± 8.71 79.14 ± 4.85 81.24 ± 13.01 63.60 ± 5.82#† 63.33 ± 8.71#† 
HDL 
cholesterol 
21.71 ± 4.54 17.80 ± 1.77 24.50 ± 2.50# 18.40 ± 5.90 18.33 ± 3.14 
LDL 
cholesterol 
41.20± 9.09 41.50 ± 6.31 36.81 ± 8.90 30.56 ± 4.63 33.40 ± 5.02 
Triglycerides 61.14 ± 11.2 99.20 ± 20.2* 99.67 ± 25.3* 73.20 ± 9.37 58.00 ± 16.4# 
Data are shown as mean ± SD of 7 animals.*p < 0.05 vs. NC, #p < 0.05 vs. FR10+STZ, †p < 
0.05 vs. FR10+STZ+MTL. (Tukey-Kramer multiple range post-hoc test).  
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3.3.9 Liver function enzymes and serum creatinine 
Table 8 represents the liver function enzymes of the animal groups at the end of the 
experimental period. No statistical differences were noted for AST amongst the groups. 
FR10+STZ and FR10+STZ+MTH displayed significantly higher ALT concentrations 
compared to the NC group. No statistical differences in serum creatinine were noted amongst 
the experimental groups. 
Table 8: Serum AST, ALT and creatinine levels at the end of the experimental period. 
Rat group Normal 




















34.86 ± 6.4 
0.43 ± 0.1 
65.20 ± 21.7* 
0.38 ± 0.1 
53.83 ± 13.7 
0.39 ± 0.1 
62.20 ± 17.8* 
0.41 ± 0.1 
59.33 ± 13.8 
0.44 ± 0.03 
 
Data are shown as mean ± SD of 7 animals. *p < 0.05 vs. NC. (Tukey-Kramer multiple range 
post-hoc test). AST: aspartate transaminase, ALT: alanine transaminase 
 
3.3.11 Glycated protein, total protein, serum albumin and uric acid 
Table 9 shows the serum protein profile and uric acid of the different animal groups at the 
end of the experimental period. No statistical differences were seen among groups for 
fructosamine. All diabetic groups displayed significantly lower total proteins than the NC 
group, and in addition, all treatment groups (FR10+STZ+MTL, FR10+STZ+MTH and 
FR10+STZ+CARN) displayed significantly lower total protein compared to the FR10+STZ 
group. The treatment groups also displayed significantly lower serum albumin compared to 
the NC group, but not compared to the FR10+STZ group, which in itself, was not statistically 
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different from NC. FR10+STZ+MTL and FR10+STZ+CARN displayed significantly lower 
uric acid levels compared to the NC group, but not compared to the FR10+STZ group.  





























223.7 ± 26.7 
 
6.43 ± 0.4 
 
2.66 ± 0.3 
 
2.71 ± 1.1 
242.0 ± 20.4 
 
5.58 ± 0.2* 
 
2.47 ± 0.2 
 
1.90 ± 0.9 
246.0 ± 17.1 
 
4.88 ± 0.3*# 
 
2.28 ± 0.1* 
 
1.55 ± 0.4* 
233.0 ± 21.9 
 
4.78 ± 0.2*# 
 
2.25 ± 0.1* 
 
1.76 ± 0.2 
238.3 ± 32.6 
 
4.97 ± 0.2*# 
 
2.29 ± 0.1* 
 
1.42 ± 0.2* 
 
Data are shown as mean ± SD of 7 animals. *p < 0.05 vs. NC, #p < 0.05 vs. FR10+STZ. 











Type 2 diabetes (T2D) is a growing public health threat, with an estimated 171 million people 
suffering with T2D worldwide in 2000 and this figure is expected to double to 366 million by 
2030 (WHO, 2010).  Due to the rapidly rising numbers of T2D patients, intensive research on 
diabetes therapy and prevention has similarly increased. Currently, oral drug therapies for 
T2D focus on improving insulin secretion and improving insulin sensitivity (Islam and Choi, 
2008). Recently there has been an increase in the field of alternative therapies as many drug 
regimes do not always provide satisfactory glycemic control or prevent later diabetic 
complications, in addition to the adverse effects produced by many T2D drugs. Natural 
therapies are thus increasingly sought after by health professionals and patients as an 
alternative to supplement or replace current regimes to lessen the adverse effects of 
conventional therapy (Dey et al., 2002). 
Tea in traditional Asian medicine is believed to promote both good health and longevity 
(Yang and Landau, 2000). In recent years, leaves from the mulberry plant have gained much 
popularity as a tea drink for diabetics in many Asian countries (Butt et al., 2008). The major 
anti-diabetic compound in mulberry leaves is a glucose analogue called 1-deoxynojirimycin 
(DNJ), which inhibits the intestinal enzyme α-glucosidase by binding to the active site in the 
enzyme (Kojima et al., 2010). Alpha-glucosidase is considered to be one of the most 
important enzymes in starch digestion in the small intestine and its inhibition reduces the rate 
of carbohydrate digestion to prevent extremely elevated blood glucose (BG) levels 
(Herscovics, 1999). 1-deoxynojirimycin (DNJ) is thus believed to be responsible for the 
reduction in NFBG and hyperglycemia by reducing the rate of both carbohydrate and lipid 
absorption (Kojima et al., 2010).  
It has been reported that a minimal dose of 6 mg of mulberry DNJ is required to reduce 
NFBG and decrease insulin secretions (Kimura et al., 2007; Vichasilp et al., 2011). Recently 
Vichasilp et al. (2011) investigated 35 Mulberry tea varieties in Thailand to determine and 
develop a mulberry tea blend with the optimal DNJ concentration. Several critical findings 
were established, including determining the selection of leaf area is essential to the level of 
medicinal potential. Shoots of mulberry leaves contained significantly higher DNJ content 
than young leaves, which in turn, had significantly higher DNJ content than older mulberry 
leaves (shoots > young leaves > mature leaves). These findings distinguished better 
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commercial varieties from those with insufficient DNJ concentrations to elicit any beneficial 
effect on hyperglycemia.  
Moreover, they tested the quality of the tea-making protocol provided by the manufacturers 
for DNJ extraction at 90 ºC for 300 s. They found an 85% extraction of DNJ from the dry tea 
material. However, upon modification of the protocol, the optimal tea-making condition was 
in fact found to be at 98 ºC for 400 s and this increased DNJ extraction to 95%. According to 
Vichasilp et al. (2011), this modification resulted in 0.25 L mulberry tea to be sufficient to 
provide 6.5 mg DNJ extract and hence sufficient to elicit hypoglycaemic effects. In other 
words, a 95% DNJ extraction is equivalent of providing 6.5 mg DNJ in 0.25 L of tea, which 
is only 0.5 mg higher than the minimum required dose to provide any hypoglycaemic effect. 
This indicates any inferior mulberry leaf selections in tea harvesting and/or coupled with 
incorrect preparation would most likely provide tea brews containing less than 6.5 mg DNJ 
and hence little or no anti-diabetic effect is likely to be noted. A major limitation of many 
mulberry tea brands is the non-specification of an effective dose to reduce NFBG, despite the 
packaging claims of anti-hyperglycemic effects of the tea (Kimura et al., 2004). Furthermore, 
Vichasilp et al. (2011) acknowledged the fact that for daily home-use it is largely impractical 
to measure precise tea-brewing temperatures for a specified time period in order to ensure 
sufficient active ingredients are obtained.  
For this reason, despite much literature indicating the hypoglycemic effects (Andallu and 
Varadacharyulu, 2003; Kong et al., 2008; Miyahara et al., 2004; Naowaboot et al., 2009) of 
mulberry leaf tea and extracts, it is most likely that the brand of tea used in this experiment 
might not provide sufficient DNJ to reduce NFBG as seen in Figures 29 and 30 and did not 
benefit in the glucose tolerance ability as seen in Figure 32. There is, however in fact no 
record of brewed mulberry leaf tea tested in an animal model for T2D, with most of the 
studies having dosed the extract itself, or isolating and dosing DNJ into experimental animals 
to examine the anti-diabetic effects (Kim et al., 1999; Kimura et al., 2007; Kong et al., 2008; 
Naowaboot et al., 2009). Although the result is unexpected for our experiment, it brings light 
to the importance for future studies that will be conducted on teas for anti-diabetic activities. 
At the same time, consumers need to be aware of highly varying qualities of tea as well as 




Having described earlier the two major pathogeneses of T2D as insulin resistance and partial 
pancreatic β-cell dysfunction characterised by overt hyperglycemia, achieving glycemic 
control is critical to the management of T2D (Fowler and Deepa, 2010). The failure to do so 
in this experiment by mulberry leaf tea would result in failure to correct decreased serum 
insulin as seen in Figure 33, increased liver glycogen as seen in Table 6 as well as other 
minor symptoms of T2D, namely polyphagia, polydipsia and body weight gain as seen in 
Figures 25-27.  
In line with Kojima et al. (2010) who tested mulberry leaf extract in healthy non-diabetic 
human subjects and found no significant differences in serum triglyceride levels after 12 
weeks, our results also showed no significant changes in serum triglycerides compared to the 
FR10+STZ group, although FR10+STZ+MTL, but not FR10+STZ+MTH, was significantly 
higher than NC. In addition, in healthy human subjects they found no significant differences 
in total cholesterol, HDL and LDL after both 6 and 12 weeks. Our results demonstrated no 
significant differences in total cholesterol in FR10+STZ+MTL compared to NC and 
FR10+STZ, but significantly lower total cholesterol in FR10+STZ+MTH compared to 
FR10+STZ+MTL and STZ. This may be due to the higher concentration of DNJ found in 
FR10+STZ+MTH compared to FR10+STZ+MTL, which has been shown to be effective in 
decreasing lipid accumulation in rats by β-oxidation, as DNJ is known to increase 
adiponectin and activate AMP-activated protein-kinase (AMPK) (Tsuduki et al., 2009). This 
is important as low serum adiponectin is associated with insulin resistance in several animal 
models (Diez and Iglesias, 2003). 
On the other hand, L-carnitine (CARN), unlike mulberry leaf tea, does not primarily function 
to reduce blood glucose, but rather, acts in the reversal of insulin resistance through the 
normalization of lipid profiles. Several studies have shown that CARN supplementation 
improves lipid profiles (Cha, 2008; Mondola et al., 1988; Vacha et al., 1983; Winter et al., 
1995) and reduces insulin resistance in humans and experimental animals (Mingrone et al., 
1999; Rajasekar et al., 2005; Rajasekar and Anuradha, 2007). The results seen in Table 7 
confirm these previous reports, particularly emphasising CARN’s effectiveness in 
normalizing triglyceride levels. In this experiment, the FR10+STZ+CARN group had 
significantly lower serum triglycerides compared to FR10+STZ, and interestingly, even 
lower serum triglycerides than the NC group, although this result was non-significant, 
testifying to its great potential to restore triglyceride levels. Restoration of triglyceride levels 
is important as these lipids are a significant contributor to hyperlipidemia and related 
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metabolic disturbances that disrupt insulin signalling resulting in insulin resistance (Barnes 
and Miner, 2009). This signifies CARN’s potential to reverse insulin resistance and/or be a 
useful preventative agent against the development of insulin resistance. In addition to this, 
FR10+STZ+CARN significantly reduced total cholesterol compared to FR10+STZ, and 
similarly to triglyceride concentrations, was also non-significantly lower than the NC, 
testifying to CARN’s suitability as a hypocholesterolemic agent.  
Insulin resistance is caused as a result of hyperlipidemia i.e. hypertriglyceridemia, 
hypercholesterolemia and high levels of circulating free fatty acids (FFAs). Human studies in 
pregnant women supplemented with 2g CARN/day significantly reduced plasma FFAs, 
thereby successfully preventing insulin resistance and the development of gestational diabetes 
(Lohninger et al., 2009). The mechanism by which CARN achieves this is complex (Figure 
35). CARN reduces the intramitochondrial acyl-CoA/CoA ratio (Rajesekar and Anuradha, 
2007) by promoting fatty acid β-oxidation to acetyl CoA (Figure 35, point 1). The acetyl CoA 
combines with CARN to form acetylcarnitine by the transfer of acetyl groups catalysed by 
carnitine-acetyltransferase (CAT) (Figure 35, point 2). This reduction in the acyl-CoA/CoA 
ratio activates pyruvate dehydrogenase (Calvani et al., 2000) (Figure 35, point 1), which 
subsequently decreases intracellular concentrations of citrate (Figure 35, point 2). Because 
citrate is a key regulator of the glycolytic enzyme phosphofructokinase (PFK), decreases in 
citrate cause an activation of PFK (Figure 35, point 3), leading to a stimulation of the 
glycolytic pathway and subsequent glucose metabolism. This essentially clears glucose from 
the bloodstream leading to a reduction in blood glucose (BG) (Calvani et al., 2000). 
Figure 34: Role of CARN in transport of long-chain fatty acids for β-oxidation (Taken 
without permission from Vaz and Wanders, 2002).  
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Figure 35: Role of CARN in stimulation of glycolysis and blood glucose reduction 
(Image self-drawn, adapted and modified without permission from Shulman, 2000).  
Research has shown previously of CARN’s ability to improve glucose disposal in T2D 
patients (Capaldo et al., 1991; Mingrone et al., 1999) by decreasing circulating FFAs and 
improving insulin sensitivity (Capaldo et al., 1991; Rajasekar et al., 2005).  The results 
obtained in Figure 31 display no significant improvement in NFBG reduction, although there 
is a definite non-significant trend toward NFBG reduction, with one animal in this group 
having fully recovered from overt hyperglycemia within 3-4 weeks (NFBG 421 mg/dl in 
week 1, 144 mg/dl in week 3, 179 mg/dl in week 4 of the intervention trial) and another 
animal having reduced NFBG from 600 mg/dl in week 1 to 365 mg/dl in week 4 of the 
intervention period. These results are intriguing and this leads to much speculation over the 
success of only 2 of the 7 animals in this group. Supporting the above theory, the animal that 
recovered fully also displayed the lowest total cholesterol and serum triglycerides of the 
animals in this group.  
In addition to improving lipid profiles and glucose disposal, CARN has previously been 
found to increase the rate of weight loss in overweight and obese cats (Center et al., 2000). 
Although in our experiment, at the end of the intervention trial period the FR10+STZ+CARN 
group had not technically lost weight, the mean weight gain of this group was 10.00g and 
FR10+STZ+CARN gained the least amount of weight among the animal groups. Taking into 
account that these are developing and growing rats, one could speculate that in fully 
developed adult rats this might be translated into weight loss. Furthermore, the 
FR10+STZ+CARN group did in fact lose weight between weeks 4-6 of the experimental 
period (Figure 27).  
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Although hyperglycemia and hypercholesterolemia are the two major contributing factors to 
the severity of the diabetic condition, it is necessary to analyse other vital biochemical 
parameters in order to fully assess the anti-diabetic effects of mulberry leaf tea and CARN. In 
terms of mulberry leaf tea, higher concentrations of DNJ were provided in the brewed tea in 
the case of the FR10+STZ+MTH group, thus it is prudent to bear in mind that this may 
increase toxicity due to higher trace elements such as mercury, cadmium and arsenic 
(Nookabkaew et al., 2006) as well as toxic secondary plant metabolites such as pyrrolizidine 
alkaloids (Manteiga et al., 1997) commonly found in herbal teas. In order to assess toxicity, 
liver function enzymes as markers for hepatotoxicity, liver disease and damage were 
analysed. Alanine transaminase (ALT) and aspartate transaminase (AST) are two common 
liver enzymes that indicate hepatocyte injury that have leaked into circulation as a result of 
the disease. Mild but chronic increases of these transaminases are also commonly seen in 
T2D due to hepatic insulin resistance from elevated levels of circulating free fatty acids, 
which in fact, are toxic to hepatocytes, presumably due to oxidative stress from lipid 
peroxidation and the recruitment of inflammatory cells (Harris, 2005). Mulberry leaf tea has 
been described as hepatoprotective due to its antioxidant potential (El-Beshbishy et al., 
2006). However, in this study, no significant difference was seen between the 
FR10+STZ+MTL group and the NC group verifying these previous claims, although this 
may only be relevant to low doses. FR10+STZ+CARN, like FR10+STZ+MTL did not 
display any significant differences from either the NC or FR10+STZ group, however was 
non-significantly lower than FR10+STZ, indicating an improved liver function compared to 
FR10+STZ. CARN is sometimes found to be deficient in T2D, however it is capable of 
preventing liver injury as seen in Table 8 due to its potent antioxidant activity. Because 
CARN is involved in transportation of free fatty acids (FFAs) for β-oxidation, less FFAs are 
available for peroxidation, that otherwise generate oxidative stress and cause liver damage 
(Flanagan et al., 2010, Rajasekar et al., 2005). In a study conducted by Fallon et al. (2008) 
using a mixture of black (50%), green (20%) and mulberry leaf (30%) tea extracts, ALT but 
not AST in the 3.0% and 6.0% extract-dosed groups was significantly higher than the control 
group, indicating possible heptatotoxicity, similar to that seen in FR10+STZ+MTH but not 
FR10+STZ+MTL in this study compared to the NC group, however neither were statistically 
different from the FR10+STZ group. Fallon et al. (2008) state however that given the mixture 
of extracts, it is not possible to identify the source of the toxicity, and in addition, the fact that 
the dosage correlates to quantities that would be extremely high for human consumption 
levels, which may be similar to that of hepatic necrosis seen in humans with the large 
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ingestion of tea extracts. In this experiment, it is not possible to conclude whether it is high 
levels of toxic trace elements in the tea, or whether it is simply an indication of insulin 
resistance as seen in FR10+STZ (Table 8) and in the previous study FR10 group in Table 4. 
It is, however, more likely to be an indication of insulin resistance as opposed to 
hepatotoxicity due to the fact that ALT levels in FR10+STZ+MTH are not significantly 
different from FR10+STZ.  
Besides insulin resistance, serum creatinine is a measure of kidney function as glomerular 
hyperfiltration is associated with low serum creatinine as well as increased risk for metabolic 
syndrome and T2D (Hjelmesaeth et al., 2010). No significant differences were noted amongst 
the groups, despite the model development having significantly lower serum creatinine in 
STZ and FR10+STZ compared to the NC group in the previous study (Table 4). It is possible 
that the STZ+FR10 and NC groups in this study did not reveal significant differences due to 
the three week shorter duration of this study, thus lessening the progression of the disease 
state. 
Uric acid is new risk factor for the prediction of T2D (Dehghan et al., 2008), with studies 
showing that moderate hyperglycemia is positively associated with higher uric acid levels, 
whilst overt hyperglycemia and established T2D is in fact associated with lower uric acid 
(Yuan et al., 2011). Conversely, high serum uric acid is also a predictor for diabetic 
complications related to hypertension and cardiovascular disease (Dehghan et al., 2008).  
Despite these seemingly conflicting parameters, both mulberry leaf and CARN have been 
found to possess hypouricemic potential (Yadav and Nade, 2008, Flanagan et al., 2010). A 
major glycoside of Mulberry plants is mulberroside A, which has been used in Traditional 
Chinese Medicine for the treatment of gout and hyperuricemia (Wang et al., 2011). Wang et 
al. (2011) found mulberroside A in mulberry plants decreased serum albumin and decreased 
serum uric acid levels in mice. Amin and Nagy (2009) found administration of 250 mg/kg 
BW/day CARN significantly decreased serum uric acid and serum urea in high-fat-fed rats 
after 4 weeks. As a common indicator to insulin resistance, high uric acid also accelerates the 
development of kidney disease in animals (Cirillo et al., 2006). CARN has shown therapeutic 
benefit in the prevention of kidney disease and related disorders seen in T2D by 
counteracting the changes seen in lipid metabolism (Rajasekar et al., 2008). Table 9 confirms 
the hypouricemic potential of both mulberry leaf tea and FR10+STZ+CARN as both had 
significantly lower serum uric acid compared to the NC group, and non-significantly lower 
serum uric acid compared to FR10+STZ. It is thus hard to establish whether these low results 
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correlate to extreme hyperglycemia and established T2D or as a result of their potent 
hypouricemic activity. This once again emphasizes the importance of a holistic analysis of all 
biochemical parameters as opposed to interpreting a single test result. 
The fructosamine test is another test that is the result of a non-enzymatic reaction between 
glucose and amino acids in the serum and is an early glycation product (Cheng-Tzu 2005). 
Fructosamine can thus be used to predict the concentration of advanced end glycation 
products (AGES) and is an indicator of glycemic control over a 3 week period (Li and Yang, 
2006). Studies indicate that in diabetic animals, fructosamine concentrations increase 
compared to normal controls (Cheng-Tzu 2005). Low serum fructosamine thus indicates a 
good glycemic control and in the case of intervention trials, the effectiveness of the treatment 
regime. However, low fructosamine could also be an indicator of low serum proteins 
(Browner et al., 1999) and thus results should not be analysed individually and must be 
compared in an overall manner to serum albumin and total proteins. For this reason, 
fructosamine may be falsely low, when combined with low serum albumin and low total 
proteins. This can be indicative of liver or kidney disorders as well as poorly controlled 
diabetes. Poorly controlled T2D is associated with altered protein profiles in the body as both 
reduced circulating insulin and insulin resistance can lead to muscle wasting, denoted by low 
serum proteins (Castaneda et al., 2000). However, because serum creatinine is directly 
proportional to muscle mass (Harita 2009), and our results showed no significant differences 
in serum creatinine, it is unlikely that the cause of low serum proteins is as a result of muscle 
wasting, and more likely, as a result of poorly controlled diabetes in the case of mulberry leaf 
tea and FR10+STZ+CARN. 
It is difficult to draw solid conclusions of the effectiveness of mulberry leaf tea and CARN 
based on the serum tests alone. Individually, the test results may lead one to believe that there 
is good glycemic control, as in the case of the fructosamine tests. However, in conjunction 
with serum protein profiles and low uric acid, it is more indicative of falsely low results that 
are actually a result of poorly controlled diabetes.  
In summation, mulberry leaf tea did not exhibit any hypoglycemic effects, contrary to many 
literature reports possibly due to the inferior blend of tea selection and hence was unable to 
correct minor symptoms of T2D including polyphagia, polydipsia, weight gain and liver 
glycogen as well as major symptoms including glucose intolerance and insulin deficiency. In 
accordance with other reports, it did not significantly affect the lipid profile, however did 
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significantly increase serum liver function enzyme ALT, as well as significantly decreasing 
serum total protein and albumin and serum uric acid – the combined effect thus indicating 
poorly controlled diabetes and signifying insulin resistance. In conclusion, mulberry leaf tea 
did not display any significantly beneficial anti-diabetic effects at least in this experimental 
condition and further studies involving teas need to be carefully analysed to determine 
concentrations of active compounds. Attention to manufacturer’s tea-brewing protocols also 
need to be tested and analysed for scientific merit.  
On the other hand, although FR10+STZ+CARN had no significant hypoglycaemic effects, it 
appears to have slowly non-significantly reduced NFBG over the 4 week intervention period, 
and in addition, significantly reduced some minor symptoms of T2D including polydipsia and 
resulting in a much less, albeit non-significant, weight gain. Similarly to mulberry leaf tea, it 
did not significantly affect major symptoms such as glucose intolerance and insulin 
deficiency, although these results were non-significantly better than mulberry leaf tea and the 
FR10+STZ group. Coupled with elevated liver enzymes, decreased serum protein and uric 
acid, CARN is not effective as a single agent to affect glycemic control significantly. CARN, 
however, was highly effective in normalizing serum lipid profiles, particularly triglycerides, 
which may aid in the reversal of insulin resistance and prevention of later T2D complications 
like hypertension and atherosclerosis. Its potent antioxidant activity may also be beneficial in 
prevention of renal disease (nephropathy) and neuropathy. The success of CARN in 
normalizing serum lipid profiles indicates its great potential for insulin-resistant-pre-diabetic 
patients as well as prevention of gestational diabetes, which may indirectly improve glucose 
disposal in these types of patients but not in chronic diabetic patients. While CARN 
supplementation alone is not enough to allow for the successful management of T2D, it 
should be recommended as an additional supplement to conventional drug therapy. The fact 
that CARN is naturally produced in the body is also advantageous as in diseased states; 
impairment in endogenous synthesis can be replaced through exogenous dietary consumption 
without causing serious side effects caused by synthetic drugs. Future studies should be 
conducted to determine CARN’s ability to prevent insulin resistance in healthy subjects or 






Chapter 4 General discussion  
The most successful intervention materials should reverse insulin resistance and prevent 
partial pancreatic β-cell dysfunction. Ideal alternative therapies must exhibit a similar degree 
of efficacy compared to conventional drug therapy, however without the negative side effects 
often associated with them (Dey et al., 2002). With over 400 reported traditional medicines 
for the treatment of T2D, The World Health Organization Expert Committee on diabetes has 
recognised the great potential of natural plants and functional foods as alternative treatments 
for T2D and has recommended further investigations to be carried out in support of them 
(Bailey and Day, 1989). Unfortunately results using traditional plants or functional foods 
have been difficult to replicate as many studies have utilized non-standardized forms of the 
compounds. There is thus an urgent need for standardization to allow for successful 
conclusions to be drawn (Dey et al., 2002).  
In order for this to be achieved, an ideal method of testing these compounds needs to be 
available to researchers. Studies into disease mechanistics and patterns have exponentially 
expanded, with the majority of the work performed on animal models (Wall and Shani, 
2008). This is because the biochemical pathways in mammals are largely conserved, allowing 
researchers to predict the outcome in humans. Animal model development thus plays a 
pivotal role as the foundation for good research in human diseases.  
The perfect model for T2D would ideally be inexpensive, easy to develop and simple to 
maintain along with the identical biochemical profile (hyperglycemia, decreased serum 
insulin and creatinine, hypercholesterolemia, elevated liver enzymes and liver glycogen) as 
well as demonstrating the clear pathogeneses of T2D in chronological order of development 
in humans, insulin resistance and then development of partial pancreatic β-cell dysfunction. 
Although there are some models available for specified research of a single pathogenesis or a 
later complication, unfortunately, to date, no single model demonstrates all of the above listed 
characteristics (Islam and Loots, 2009).  
The model developed in this study thoroughly examined all necessary parameters seen in the 
pathogenesis of T2D and demonstrated in chronological order, the development of insulin 
resistance and later, partial pancreatic β-cell dysfunction. Biochemical analyses revealed 
satisfactory results within the parameters for the profile of human T2D. No tests however 
were performed to assess its suitability for later diabetic complications such as nephropathy, 
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neuropathy, retinopathy and cardiomyopathy, thus one cannot speculate on its use for chronic 
diabetic studies.  
For acute studies however, such as studies on the anti-diabetic effects of plant and functional 
foods, it was therefore necessary to validate the newly developed model through a therapeutic 
intervention trial. The results of the intervention trial demonstrated both suitability of this 
model of further and future acute studies as well as concurrently adding critical research to 
the body of knowledge on functional foods and plant therapies.  
In conclusion, the model developed may be a useful, novel, non-genetic alternative model for 
T2D characterized by all major pathogeneses. The model additionally provided highly 
satisfactory results when validated through an intervention trial. The intervention trial 
revealed that mulberry leaf tea and CARN are not suitable as a substitute therapy for T2D, 
but may in some cases, be beneficial in combination with conventional drug therapy. Future 
studies should be conducted on these intervention materials to determine the most effective 
dosage in treating T2D symptoms as well as assess their effect in other areas related to this 
disease. Future studies should also most definitely be performed on this model to assess and 
determine its suitability for more broad scale studies, particularly those involving chronic 
diabetic complications. The biggest advantage that already exists for chronic studies is the 
cheap and simple development and well as low maintenance costs when using this model, 
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